var docs;if (!docs) docs =[]; docs["32"]={"3200":"<p><b>Title</b> Neuromuscular-Blocking Agents (Nondepolarizing) / Acetylcholinesterase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Acetylcholinesterase Inhibitors may diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). <b>Severity</b> Moderate <b>Onset</b> Immediate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for reduced effects of nondepolarizing neuromuscular-blocking agents (NonDNMBAs) if used concomitantly with acetylcholinesterase inhibitors. This interaction is often used intentionally to reverse the effects of NonDNMBAs. Patients receiving acetylcholinesterase inhibitors (e.g., for dementia) may not adequately respond to NonDNMBAs until acetylcholinesterase inhibitor effects have worn off (see prescribing information for the individual agent for duration of action).</p>\n<div>\n <p><b>Acetylcholinesterase Inhibitors Interacting Members</b> Distigmine, Donepezil, Edrophonium, Galantamine, Neostigmine, Physostigmine, Pyridostigmine, Rivastigmine</p>\n <p><b>Neuromuscular-Blocking Agents (Nondepolarizing) Interacting Members</b> Atracurium, Cisatracurium, Mivacurium, Pancuronium, Rocuronium, Vecuronium</p>\n</div> \n<p><b>Discussion</b> Several case reports and clinical studies have described reduction or reversal of neuromuscular blocking effects of nondepolarizing neuromuscular-blocking agents (NonDNMBAs) following administration of acetylcholinesterase inhibitors.<sup>1,2,3,4,5,6</sup><br><br>NonDNMBAs inhibit initiation of muscular action potentials via competition with acetylcholine for binding at neuromuscular endplate receptors. Inhibition of acetylcholinesterase, an enzyme that hydrolyzes the acetylcholine in the neuromuscular junction to choline and acetic acid, counteracts this mechanism by increasing junctional acetylcholine concentrations. Of note, one case report of enhanced (rather than reduced) succinylcholine/vecuronium neuromuscular blockade following administration of neostigmine likely reflects neostigmine inhibition of pseudocholinesterase mediated succinylcholine metabolism rather than a paradoxical interaction with vecuronium.<sup>7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Dhonneur G, Rebaine C, Slavov V, et al, “Neostigmine Reversal of Vecuronium Neuromuscular Block and The Influence of Renal Failure,” <i>Anesth Analg</i>, 1996, 82(1):134-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8712389\">[PubMed 8712389]</a></p>\n<p>2. Rautoma P, Erkola O and Meretoja OA, “Potency and Hourly Maintenance Requirement of Combinations of Mivacurium and Pancuronium in Adults,” <i>Can J Anaesth</i>, 1998, 45(3):212-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9579257\">[PubMed 9579257]</a></p>\n<p>3. Russell WJ, “The Impact of Alzheimer's Disease Medication on Muscle Relaxants,” <i>Anaesth Intensive Care</i>, 2009, 37(1):134-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19160552\">[PubMed 19160552]</a></p>\n<p>4. Baruaah J, Easby J and Kessell G. “Effects of Acetylcholinesterase Inhibitor Therapy for Alzheimer's Disease on Neuromuscular Block,” <i>Br J Anaesth</i>, 2008, 100:420. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18276655\">[PubMed 18276655]</a></p>\n<p>5. Morita T, Kurosaki D, Tsukagoshi H, et al, “Factors Affecting Neostigmine Reversal of Vecuronium Block During Sevoflurane Anaesthesia,” <i>Anaesthesia</i>, 1997, 52(6):538-43. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9203879\">[PubMed 9203879]</a></p>\n<p>6. Sacan O, White PF, Tufanogullari B, et al, “Sugammadex Reversal of Rocuronium-Induced Neuromuscular Blockade: A Comparison With Neostigmine-Glycopyrrolate and Edrophonium-Atropine,” <i>Anesth Analg</i>, 2007, 104(3):569-74. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17312210\">[PubMed 17312210]</a></p>\n<p>7. Ramirez JG, Sprung J, Keegan MT, et al, “Neostigmine-Induced Prolonged Neuromuscular Blockade in a Patient with Atypical Pseudocholinesterase,” <i>J Clin Anesth</i>, 2005, 17(3):221-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15896593\">[PubMed 15896593]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3201":"<p><b>Title</b> Beta-Blockers / Acetylcholinesterase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Acetylcholinesterase Inhibitors may enhance the bradycardic effect of Beta-Blockers. <b>Severity</b> Moderate <b>Onset</b> Immediate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased bradycardia, syncope, and/or hypotension in patients receiving concomitant therapy with beta-blockers and an acetylcholinesterase inhibitor.</p>\n<div>\n <p><b>Acetylcholinesterase Inhibitors Interacting Members</b> Distigmine, Donepezil, Edrophonium, Galantamine, Neostigmine*, Physostigmine*, Pyridostigmine, Rivastigmine</p>\n <p><b>Beta-Blockers Interacting Members</b> Acebutolol, Arotinolol, Atenolol*, Betaxolol (Ophthalmic), Betaxolol (Systemic), Bisoprolol, Carteolol (Ophthalmic), Carvedilol, Celiprolol, Esmolol, Labetalol, Metoprolol, Nadolol*, Nebivolol, Oxprenolol, Penbutolol, Pindolol, Propranolol*, Sotalol, Timolol (Ophthalmic), Timolol (Systemic)<br><b>Exceptions</b> Levobunolol, Metipranolol</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Several case reports describe the development of severe bradycardia and hypotension in patients taking beta-blockers when administered with an acetylcholinesterase inhibitor as a reversing agent for neuromuscular blockade.<sup>1,2,3,4,5</sup> Other reports describe the development of syncope, bradycardia and sinus pauses with the use of rivastigmine and atenolol,<sup>6</sup> and the development of complete heart block with the use of rivastigmine alone.<sup>7</sup> In contrast, 2 days of concomitant beta-blocker and pyridostigmine (30 mg 3 times/day) in 8 patients failed to show any cardiovascular effects.<sup>8</sup> <br><br>The mechanism of this interaction is likely additive bradycardic effects of the beta-blocker and acetylcholine (present in higher concentrations due to the acetylcholinesterase inhibitor).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Baraka A, Dajani A. Severe bradycardia following physostigmine in the presence of beta-adrenergic blockade-a case report. <i>Middle East J Anaesthesiol</i>. 1984;7(4):291-293. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6148684\">[PubMed 6148684]</a></p>\n<p>2. Eldor J, Hoffmann B, Davidson JT. Prolonged bradycardia and hypotension after neostigmine administration in a patient receiving atenolol. <i>Anaesthesia</i>. 1987;42(12):1294-1297. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3434760\">[PubMed 3434760]</a></p>\n<p>3. Seidl DC, Martin DE. Prolonged bradycardia after neostigmine administration in a patient taking nadolol. <i>Anesth Analg</i>. 1984;63(3):365-367. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6703355\">[PubMed 6703355]</a></p>\n<p>4. Sprague DH. Severe bradycardia after neostigmine in a patient taking propranolol to control paroxysmal atrial tachycardia. <i>Anesthesiology</i>. 1975;42(2):208-210. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1115373\">[PubMed 1115373]</a></p>\n<p>5. Wagner DL, Moorthy SS, Stoelting RK. Administration of anticholinesterase drugs in the presence of beta-adrenergic blockade. <i>Anesth Analg</i>. 1982;61(2):153-154. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6119932\">[PubMed 6119932]</a></p>\n<p>6. Paulison B, Leos CL. Potential cardiotoxic reaction involving rivastigmine and beta-blockers: a case report and review of the literature. <i>Cardiovasc Toxicol</i>. 2010;10(4):306-310. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20865460\">[PubMed 20865460]</a></p>\n<p>7. Kayrak M, Yazici M, Ayhan SS, Koc F, Ulgen MS. Complete atrioventricular block associated with rivastigmine therapy. <i>Am J Health Syst Pharm</i>. 2008;65(11):1051-1053. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18499878\">[PubMed 18499878]</a></p>\n<p>8. Arad M, Roth A, Zelinger J, Zivner Z, Rabinowitz B, Atsmon J. Safety of pyridostigmine in hypertensive patients receiving beta-blockers. <i>Am J Cardiol</i>. 1992;69(5):518-522. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1346558\">[PubMed 1346558]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3202":"<p><b>Title</b> Calcium Channel Blockers / Barbiturates</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Barbiturates may increase the metabolism of Calcium Channel Blockers. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of calcium channel blockers if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. Alterations in calcium channel blocker dose may be necessary. The Canadian labeling for nimodipine specifically contraindicates use with phenobarbital.</p>\n<div>\n <p><b>Barbiturates Interacting Members</b> Amobarbital, Butabarbital, Butalbital, Methohexital, PENTobarbital, PHENobarbital*, Primidone, Secobarbital, Thiopental</p>\n <p><b>Calcium Channel Blockers Interacting Members</b> AmLODIPine, Barnidipine, Benidipine, Bepridil, Cilnidipine, DilTIAZem, Efonidipine, Felodipine, Isradipine, Lacidipine, Lercanidipine, Manidipine, NiCARdipine, NIFEdipine*, Nilvadipine, NiMODipine*, Nisoldipine, Nitrendipine, Verapamil*<br><b>Exception</b> Clevidipine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The clearance of nifedipine (20 mg single dose) was increased 2.75-fold in 15 normal subjects when administered following a 2-week course of phenobarbital (100 mg/day).<sup>1</sup> The mean apparent oral clearance of verapamil (following both single and multiple doses) was increased more than 4-fold in healthy volunteers after 3 weeks of concomitant therapy with phenobarbital.<sup>2</sup> Nimodipine Canadian labeling describes an approximate 80% reduction in nimodipine bioavailability in epileptic patients receiving concurrent anticonvulsant therapy that included phenobarbital.<sup>3</sup> Barbiturates are known CYP3A4 isoenzymes inducers. CYP3A4 isoenzymes are responsible for metabolizing calcium channel blockers. Concomitant therapy increases calcium channel blocker metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Schellens JH, van der Wart JH, Brugman M, et al, “Influence of Enzyme Induction and Inhibition on the Oxidation of Nifedipine, Sparteine, Mephenytoin, and Antipyrine in Humans Assessed by a ‘Cocktail’ Study Design,” <i>J Pharmacol Exp Ther</i>, 1989, 249:638-45. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2724144\">[PubMed 2724144]</a></p>\n<p>2. Rutledge DR, Pieper JA, Mirvis DM, “Effects of Chronic Phenobarbital on Verapamil Disposition in Humans,” <i>J Pharmacol Exp Ther</i>, 1988, 246(1):7-13. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3392664\">[PubMed 3392664]</a></p>\n<p>3. Product Monograph. Nimotop (nimodipine). Toronto, Ontario: Bayer Inc., April 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3203":"<p><b>Title</b> Phenytoin / Calcium Channel Blockers</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Calcium Channel Blockers may increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Calcium Channel Blockers. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for phenytoin toxicity if a calcium channel blocker (CCB) is initiated/dose increased, or decreased phenytoin effects if a CCB is discontinued/dose decreased. Monitor for reduced CCB therapeutic effects with concomitant use of phenytoin. Nifedipine labeling recommends avoiding concurrent use with phenytoin, and nimodipine Canadian labeling contraindicates concomitant use of phenytoin.</p>\n<div>\n <p><b>Calcium Channel Blockers Interacting Members</b> AmLODIPine, Barnidipine, Benidipine, Bepridil, Cilnidipine, DilTIAZem*, Efonidipine, Felodipine, Isradipine, Lacidipine, Lercanidipine, Manidipine, NiCARdipine, NIFEdipine*, Nilvadipine, NiMODipine*, Nisoldipine*, Nitrendipine, Verapamil*<br><b>Exception</b> Clevidipine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Signs of phenytoin toxicity developed within 2 weeks of initiating diltiazem therapy in a patient who had been receiving phenytoin according to a published case report.<sup>1</sup> Similarly, adverse effects were also reported in 3 of 16 patients receiving phenytoin with diltiazem, verapamil, or nifedipine (all adverse effects were reported in diltiazem-treated patients) in a retrospective analysis of patients receiving anticonvulsants together with calcium channel blockers.<sup>2</sup> Another patient's serum phenytoin concentrations were approximately 3-fold higher with concurrent nifedipine in another case report.<sup>3</sup> It appears as though calcium channel blockers may affect phenytoin clearance, likely via inhibition of CYP3A4 (e.g., diltiazem) and/or changes in hepatic blood flow (e.g., nifedipine).<br><br>Phenytoin, as an inducer of CYP3A4 and other drug metabolizing enzymes, also may affect the clearance of calcium channel blockers. The AUC of felodipine was approximately 94% lower in 10 patients also taking anticonvulsants (some of which were taking phenytoin alone) compared to 12 control patients.<sup>4</sup> The AUC (normalized) of nisoldipine (single 20 mg or 40 mg dose) was reduced nearly 90% in 12 patients also receiving phenytoin compared to 12 controls.<sup>5</sup> Another patient failed to achieve adequate serum verapamil concentrations until withdrawal of phenytoin therapy.<sup>6</sup> Nimodipine Canadian labeling describes an approximate 80% reduction in nimodipine bioavailability among epileptic patients receiving concurrent anticonvulsant therapy that included phenytoin.<sup>7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Clarke WR, Horn JR, Kawabori I, Gurtel S. Potentially serious drug interactions secondary to high-dose diltiazem used in the treatment of pulmonary hypertension. <i>Pharmacotherapy</i>. 1993;13(4):402-405. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8361869\">[PubMed 8361869]</a></p>\n<p>2. Bahls FH, Ozuna J, Ritchie DE. Interactions between calcium channel blockers and the anticonvulsants carbamazepine and phenytoin. <i>Neurology</i>. 1991;41(5):740-742. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2027492\">[PubMed 2027492]</a></p>\n<p>3. Ahmad S. Nifedipine--phenytoin interaction. <i>J Am Coll Cardiol</i>. 1984;3(6):1582. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6425385\">[PubMed 6425385]</a></p>\n<p>4. Capewell S, Freestone S, Critchley JA, Pottage A, Prescott LF. Reduced felodipine bioavailability in patients taking anticonvulsants. <i>Lancet</i>. 1988;2(8609):480-482. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2900404\">[PubMed 2900404]</a></p>\n<p>5. Michelucci R, Cipolla G, Passarelli D, et al. Reduced plasma nisoldipine concentrations in phenytoin-treated patients with epilepsy. <i>Epilepsia</i>. 1996;37(11):1107-1110. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8917062\">[PubMed 8917062]</a></p>\n<p>6. Woodcock BG, Kirsten R, Nelson K, Rietbrock S, Hopf R, Kaltenbach M. A reduction in verapamil concentrations with phenytoin. <i>N Engl J Med</i>. 1991;325(16):1179. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1891033\">[PubMed 1891033]</a></p>\n<p>7. Nimotop (nimodipine) [product monograph]. Toronto, Ontario, Canada: Bayer Inc.; April 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3205":"<p><b>Title</b> Tricyclic Antidepressants / Barbiturates</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Barbiturates may increase the metabolism of Tricyclic Antidepressants. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation.</p>\n<div>\n <p><b>Barbiturates Interacting Members</b> Amobarbital*, Butabarbital, Butalbital*, Methohexital, PENTobarbital*, PHENobarbital*, Primidone, Secobarbital, Thiopental</p>\n <p><b>Tricyclic Antidepressants Interacting Members</b> Amitriptyline, Amoxapine, ClomiPRAMINE, Desipramine, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Imipramine*, Lofepramine, Melitracen [INT], Nortriptyline*, Protriptyline*, Trimipramine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Serum imipramine concentrations decreased by approximately 50%, accompanied by a loss of antidepressant effects, in a patient within 2 weeks of initiating butalbital (400 mg/day).<sup>1</sup> Similarly marked reductions in serum concentrations and effects of other tricyclics have occurred when coadministered with a variety of barbiturates.<sup>2,3,4,5</sup> Barbiturates are known inducers of CYP isoenzymes which are involved in the metabolism of tricyclic antidepressants.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Garey KW, Ansden GW, and Johns CA, “Possible Interaction Between Imipramine and Butalbital,” <i>Pharmacotherapy</i>, 1997, 17:1041-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9324197\">[PubMed 9324197]</a></p>\n<p>2. Alexanderson A, Price Evans DA, and Joqvist F, “Steady State Plasma Levels of Nortriptyline in Twins: Influence of Genetic Factors and Drug Therapy,” <i>Br Med J</i>, 1969, 4:764. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5391106\">[PubMed 5391106]</a></p>\n<p>3. Burrows GD and Davies B, “Antidepressants and Barbiturates,” <i>Br Med J</i>, 1971, 4:113. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5097405\">[PubMed 5097405]</a></p>\n<p>4. Silverman G and Braithwaite R, “Interaction of Benzodiazepines and Tricyclic Antidepressants,” <i>Br Med J</i>, 1972, 4:111. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4677890\">[PubMed 4677890]</a></p>\n<p>5. Moody JP, Whyte SF, MacDonald AJ, et al, “Pharmacokinetic Aspects of Protriptyline Plasma Levels,” <i>Eur J Clin Pharmacol</i>, 1977, 11:51. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=832658\">[PubMed 832658]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3206":"<p><b>Title</b> Tricyclic Antidepressants / Rifamycin Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Rifamycin Derivatives may increase the metabolism of Tricyclic Antidepressants. <b>Severity</b> Moderate <b>Onset</b> Delayed <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of tricyclic antidepressants if a rifamycin derivative is initiated/dose increased, or increased effects if a rifamycin derivative is discontinued/dose decreased. In order of potency/risk: rifampin &gt; rifapentine &gt; rifabutin.</p>\n<div>\n <p><b>Rifamycin Derivatives Interacting Members</b> Rifabutin, RifAMPin*, Rifapentine</p>\n <p><b>Tricyclic Antidepressants Interacting Members</b> Amitriptyline, Amoxapine, ClomiPRAMINE, Desipramine, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Imipramine, Lofepramine, Melitracen [INT], Nortriptyline*, Protriptyline, Trimipramine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Case report. A tuberculosis patient (receiving isoniazid, pyrazinamide, pyridoxine, and rifampin) required 175 mg daily doses of nortriptyline in order to achieve an adequate serum concentration (193 nmol/L) and antidepressant response.<sup>1</sup> Three weeks following the eventual discontinuation of rifampin and isoniazid (pyrazinamide was discontinued earlier) the patient complained of drowsiness, and was found to have a serum nortriptyline concentration of 671 nmol/L. The nortriptyline dosage was reduced to 75 mg/day with continued efficacy and tolerance. It is presumed that rifampin, a known CYP inducer, was the cause of increased nortriptyline metabolism. The lack of additional published information regarding this interaction, in light of the frequency of use of these agents, would place the incidence of adverse events due to interactions quite low.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Bebchuk JM and Stewart DE, “Drug Interaction Between Rifampin and Nortriptyline: A Case Report,” <i>Int J Psychiatr Med</i>, 1991, 21:183-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1894457\">[PubMed 1894457]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3212":"<p><b>Title</b> Neuromuscular-Blocking Agents / Polymyxin B</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Polymyxin B may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> If possible, avoid concomitant use of these agents. Monitor for deeper, prolonged neuromuscular-blocking effects (respiratory paralysis) in patients receiving concomitant neuromuscular-blocking agents and polymyxin antibiotics (eg, colistin, polymyxin B).</p>\n<div>\n <p><b>Neuromuscular-Blocking Agents Interacting Members</b> Atracurium, Cisatracurium, Mivacurium, Pancuronium*, Rocuronium, Succinylcholine*, Vecuronium</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Several case reports describe the occurrence of neuromuscular blockade (respiratory muscle paralysis) during the use of polymyxin antibiotics (colistin (polymyxin E), and polymyxin B) with or without concomitant use of neuromuscular-blocking agents.<sup>1,2,3,4,5</sup> Calcium gluconate was effectively employed in reversing the blockade in one patient.<sup>2</sup> The polymyxins appear to possess independent neuromuscular-blocking characteristics. Concomitant therapy with a neuromuscular-blocking agent may result in deeper, prolonged effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Pittinger CB, Eryasa Y, and Adamson R, “Antibiotic-Induced Paralysis,” <i>Anesth Analg</i>, 1970, 49:487. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4102601\">[PubMed 4102601]</a></p>\n<p>2. Giala MM and Paradelis AG, “Two Cases of Prolonged Respiratory Depression Due to Interaction of Pancuronium With Colistin and Streptomycin,” <i>J Antimicrob Chemother</i>, 1979, 5:234. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=429254\">[PubMed 429254]</a></p>\n<p>3. Fogdall RP and Miller RD, “Prolongation of Pancuronium-Induced Neuromuscular Blockade by Polymyxin B,” <i>Anesthesiology</i>, 1974, 41:407. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4359101\">[PubMed 4359101]</a></p>\n<p>4. Small GA, “Respiratory Paralysis After a Large Dose of Intraperitoneal Polymyxin B and Bacitracin,” <i>Anesth Analg</i>, 1964, 43:137-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14164930\">[PubMed 14164930]</a></p>\n<p>5. Pohlmann G, “Respiratory Arrest Associated With Intravenous Administration of Polymyxin B Sulfate,” <i>JAMA</i>, 1966, 196:181. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4286165\">[PubMed 4286165]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3214":"<p><b>Title</b> Penicillins / Tetracyclines</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Tetracyclines may diminish the therapeutic effect of Penicillins. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of penicillin antibiotics if used concomitant with a tetracycline antibiotic, especially in the treatment of meningitis. If initiated at the same time, begin the penicillin at least 2 hours before the tetracycline to achieve greatest bactericidal action of penicillin. Higher doses of penicillin are less affected than lower doses.</p>\n<div>\n <p><b>Penicillins Interacting Members</b> Amdinocillin, Amoxicillin, Ampicillin, Bacampicillin, Cloxacillin, Dicloxacillin, Flucloxacillin, Nafcillin, Oxacillin, Penicillin G (Parenteral/Aqueous)*, Penicillin G Benzathine, Penicillin G Procaine, Penicillin V Benzathine, Penicillin V Potassium, Piperacillin, Temocillin, Ticarcillin</p>\n <p><b>Tetracyclines Interacting Members</b> Demeclocycline, Doxycycline, Lymecycline, Minocycline, Oxytetracycline, Tetracycline (Systemic)*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Efficacy in treating pneumococcal meningitis revealed that patients receiving penicillin alone showed a reduced rate of mortality compared to patients receiving penicillin plus a tetracycline (chlortetracycline, oxytetracycline, tetracycline).<sup>1,2</sup> Furthermore, studies evaluating the use of amoxicillin and tetracycline as part of H. Pylori regimen, found significantly reduced rates of eradication in therapies containing amoxicillin and tetracycline, when compared to control regimens.<sup>3,4</sup><br><br>A likely mechanism of this interaction is the antagonistic effects of bacteriostatic tetracyclines on bacteriacidal penicillins. Penicillins exhibit optimal bacterial killing on dividing cells, which tetracyclines inhibit, thus reducing the efficacy of penicillins. There are in vitro data both supporting and refuting this interaction.<sup>5,6,7</sup> Additionally, not all studies have found decrease efficacy with concurrent tetracycline and penicillin therapy. For example, one study found that adding tetracycline (500 mg oxytetracycline every 6 hours for 7 days) to a single dose of ampicillin (2 g) and probenecid (1 g) in patients with gonorrhea beneficial.<sup>8</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Lepper MH, Dowling HF. Treatment of pneumococcic meningitis with penicillin compared with penicillin plus aureomycin; studies including observations on an apparent antagonism between penicillin and aureomycin. <i>AMA Arch Intern Med</i>. 1951;88(4):489-494. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14867955\">[PubMed 14867955]</a></p>\n<p>2. Olsson RA, Kirby JC, and Romansky MJ. Pneumococcal meningitis in the adult. Clinical, therapeutic, and prognostic aspects in forty-three patients. <i>Ann Intern Med</i>. 1961;55:545-549. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14481954\">[PubMed 14481954]</a></p>\n<p>3. Cheon JH, Kim SG, Kim JM, et al. Combinations containing amoxicillin-clavulanate and tetracycline are inappropriate for Helicobacter pylori eradication despite high in vitro susceptibility. <i>J Gastroenterol Hepatol</i>. 2006;21(10):1590-1595. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16928222\">[PubMed 16928222]</a></p>\n<p>4. Perri F, Festa V, Merla A, Quitadamo M, Clemente R, Andriulli A. Amoxicillin/tetracycline combinations are inadequate as alternative therapies for Helicobacter pylori infection. <i>Helicobacter</i>. 2002;7(2):99-104. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11966868\">[PubMed 11966868]</a></p>\n<p>5. Li RC, Schentag JJ, Nix DE. The fractional maximal effect method: a new way to characterize the effect of antibiotic combinations and other nonlinear pharmacodynamic interactions. <i>Antimicrob Agents Chemother</i>. 1993;37(3):523-531. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8460921\">[PubMed 8460921]</a></p>\n<p>6. Elek SD, Hilson GF, Jewell P. Laboratory aspects of combined antibiotic treatment. <i>Br Med J</i>. 1953;2(4849):1298-1300. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=13106416\">[PubMed 13106416]</a></p>\n<p>7. Daschner FD. Combination of bacteriostatic and bactericidal drugs: lack of significant in vitro antagonism between penicillin, cephalothin, and rolitetracycline. <i>Antimicrob Agents Chemother</i>. 1976;10(5):802-808. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=795370\">[PubMed 795370]</a></p>\n<p>8. Ridgway GL, Oriel JD. Advantages of adding a course of tetracycline to single dose ampicillin and probenecid in the treatment of gonorrhoea. <i>Br J Vener Dis</i>. 1984;60(4):235-237. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6744010\">[PubMed 6744010]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3215":"<p><b>Title</b> Theophylline Derivatives / Pentoxifylline</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Pentoxifylline may increase the serum concentration of Theophylline Derivatives. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased concentrations/toxic effects of theophylline derivatives if pentoxifylline is initiated/dose increased, or decreased concentrations/effects if pentoxifylline is discontinued/dose decreased.</p>\n<div>\n <p><b>Theophylline Derivatives Interacting Members</b> Acebrophylline, Aminophylline, Theophylline*<br><b>Exception</b> Dyphylline</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> In a study of 9 healthy volunteers, serum theophylline (300 mg sustained release formulation twice daily) trough concentrations were increased by 30% on average when administered concomitant with pentoxifylline (400 mg 3 times/day for 7 days).<sup>1</sup> <br><br>The mechanism of this interaction is unclear. Several theophylline assays, including the one employed in the above study, have shown no assay interference in the presence of pentoxifylline and its metabolites.<sup>2,3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Ellison MJ, Horner RD, Willis SE, et al, “Influence of Pentoxifylline on Steady-State Theophylline Serum Concentrations From Sustained-Release Formulations,” <i>Pharmacotherapy</i>, 1990, 10:383-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2287557\">[PubMed 2287557]</a></p>\n<p>2. Cummings DM, Rocci ML Jr, Green P, et al, “Interference Potential of Pentoxifylline and Its Major Metabolite With Theophylline Assays,” <i>Am J Hosp Pharm</i>, 1985, 42:2717-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3909811\">[PubMed 3909811]</a></p>\n<p>3. Cohen IA, Johnson CE, Wesolowicz L, et al, “Effect of Pentoxifylline and Its Metabolites on Three Theophylline Assays,” <i>Clin Pharm</i>, 1988, 7(6):457-61. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3042268\">[PubMed 3042268]</a></p>\n<p>4. Morton MR, Parish RC and Spruill WJ, “Lack of Theophylline Assay Interference From Pentoxifylline and Its Metabolites,” <i>Ther Drug Monit</i>, 1989, 11(3):347-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2728093\">[PubMed 2728093]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3216":"<p><b>Title</b> Succinylcholine / Phenelzine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Phenelzine may enhance the neuromuscular-blocking effect of Succinylcholine. <b>Severity</b> Major <b>Onset</b> Rapid <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider a lower initial dose of succinylcholine in patients who are receiving, or have recently received (within last 2 weeks) phenelzine. Monitor for increased therapeutic effects (eg, prolonged apnea) of succinylcholine if phenelzine is being taken/or has recently been discontinued.</p> \n<p><b>Discussion</b> Case report. Phenelzine-treated patient developed prolonged apnea in response to succinylcholine administration.<sup>1</sup> The patient was discovered to have decreased plasma pseudocholinesterase concentrations. Three additional phenelzine patients were also noted to have reduced serum pseudocholinesterase concentrations. Succinylcholine metabolism is dependent upon serum pseudocholinesterase. It does not appear as though other monoamine oxidase inhibitors affect serum pseudocholinesterase concentrations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Bodley PO, Halwax K, and Otts L, “Low Serum Pseudocholinesterase Levels Complicating Treatment With Phenelzine,” <i>Br Med J</i>, 1969, 3:510. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5801348\">[PubMed 5801348]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3220":"<p><b>Title</b> Barbiturates / Primidone</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Primidone may enhance the adverse/toxic effect of Barbiturates. Primidone is converted to phenobarbital, and thus becomes additive with existing barbiturate therapy. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Primidone is metabolized to phenobarbital. Monitor for increased serum phenobarbital concentrations/effects during concomitant administration of primidone and phenobarbital, or increased barbiturate effects if administered concomitant with primidone.</p>\n<div>\n <p><b>Barbiturates Interacting Members</b> Amobarbital, Butabarbital, Butalbital, Methohexital, PENTobarbital, PHENobarbital*, Primidone*, Secobarbital, Thiopental</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Primidone is partially converted to phenobarbital <i>in vivo</i>. Concomitant administration with phenobarbital has resulted in excessive serum phenobarbital concentrations in some patients.<sup>1,2</sup> Some agents (eg, phenytoin) may increase the conversion of primidone to phenobarbital, and thus increase the risk of toxicity. Additive effects of any barbiturate and converted primidone would seem likely.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Fincham RW, Schottelius DD, and Sahs AL, “The Influence of Diphenylhydantoin on Primidone Metabolism,” <i>Arch Neurol</i>, 1974, 30(3):259-62. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4812960\">[PubMed 4812960]</a></p>\n<p>2. Griffin GD, et al, “Primidone-Phenobarbital Intoxication,” <i>Drug Ther</i>, 1976, 60:76.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3223":"<p><b>Title</b> QuiNIDine / Phenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Phenytoin may decrease the serum concentration of QuiNIDine. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased serum concentrations/therapeutic effects of quinidine if phenytoin is initiated/dose increased, or increased serum concentrations/effects if phenytoin is discontinued/dose decreased.</p> \n<p><b>Discussion</b> The AUC (a measure of drug exposure) of quinidine (300 mg single dose) was decreased by approximately 60% in 4 healthy subjects when administered following a 2-week course of phenobarbital or phenytoin.<sup>1</sup> Serum half-life of quinidine in this study, and others, has been reported to be at least halved by concurrent use of phenobarbital, phenytoin, or primidone (partially metabolized to phenobarbital).<sup>1,2,3,4</sup> <br><br>The presumed mechanism of this interaction is phenytoin induction of quinidine metabolism, likely mediated primarily by CYP3A4 but also possibly involving other enzymes such as CYP2C9.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Data JL, Wilkinson GR, and Nies AS, “Interaction of Quinidine With Anticonvulsant Drugs,” <i>N Engl J Med</i>, 1976, 294:699-702. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1250281\">[PubMed 1250281]</a></p>\n<p>2. Kroboth FJ, Kroboth PD, and Logan T, “Phenytoin-Theophylline-Quinidine Interaction,” <i>N Engl J Med</i>, 1983, 308:724-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6828116\">[PubMed 6828116]</a></p>\n<p>3. Rodgers GC and Blackman MS, “Quinidine Interaction With Anticonvulsants,” <i>Drug Intell Clin Pharm</i>, 1983, 17:819-20. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6641505\">[PubMed 6641505]</a></p>\n<p>4. Russo ME, Russo J, and Smith RA, “The Effect of Phenytoin on Quinidine Pharmacokinetics,” <i>Drug Intell Clin Pharm</i>, 1982, 16:480.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3224":"<p><b>Title</b> QuiNIDine / Primidone</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Primidone may decrease the serum concentration of QuiNIDine. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased serum concentrations/therapeutic effects of quinidine if primidone is initiated/dose increased, or increased serum concentrations/effects if primidone is discontinued/dose decreased.</p> \n<p><b>Discussion</b> The AUC of quinidine (300 mg single dose) was decreased by approximately 60% in 4 normal subjects when administered following a 2-week course of phenobarbital or phenytoin.<sup>1</sup> Serum half-life of quinidine in this study, and others, is reported to be at least halved by concurrent use of phenobarbital, phenytoin, or primidone (partially metabolized to phenobarbital).<sup>1,2,3,4</sup> <br><br>The presumed mechanism of this interaction is phenobarbital induction of quinidine metabolism, likely mediated primarily by CYP3A4 but also possibly involving other enzymes such as CYP2C9.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Data JL, Wilkinson GR, and Nies AS, “Interaction of Quinidine With Anticonvulsant Drugs,” <i>N Engl J Med</i>, 1976, 294:699. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1250281\">[PubMed 1250281]</a></p>\n<p>2. Kroboth FJ, Kroboth PD, and Logan T, “Phenytoin-Theophylline-Quinidine Interaction,” <i>N Engl J Med</i>, 1983, 308:724-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6828116\">[PubMed 6828116]</a></p>\n<p>3. Rodgers GC and Blackman MS, “Quinidine Interaction With Anticonvulsants,” <i>Drug Intell Clin Pharm</i>, 1983, 17:819-20. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6641505\">[PubMed 6641505]</a></p>\n<p>4. Russo ME, Russo J, and Smith RA, “The Effect of Phenytoin on Quinidine Pharmacokinetics,” <i>Drug Intell Clin Pharm</i>, 1982, 16:480.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3225":"<p><b>Title</b> Theophylline Derivatives / Barbiturates</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Barbiturates may decrease the serum concentration of Theophylline Derivatives. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for decreased serum concentrations/therapeutic effects of theophylline derivatives if a barbiturate is initiated/dose increased, or increased serum concentrations/effects if a barbiturate is discontinued/dose decreased.</p>\n<div>\n <p><b>Barbiturates Interacting Members</b> Amobarbital, Butabarbital, Butalbital, Methohexital, PENTobarbital*, PHENobarbital*, Primidone, Secobarbital*, Thiopental</p>\n <p><b>Theophylline Derivatives Interacting Members</b> Acebrophylline, Aminophylline, Theophylline*<br><b>Exception</b> Dyphylline</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Mean steady state serum theophylline concentrations were decreased about 30% in 7 pediatric patients following 19 days of concomitant therapy with phenobarbital (2 mg/kg/day).<sup>1</sup> The clearance increased approximately 35%. Other reports describe similar effects of phenobarbital.<sup>2,3,4</sup> The clearance of theophylline was increased 40% in 10 normal subjects following 10 days of concomitant therapy with pentobarbital (100 mg/day).<sup>5</sup> Secobarbital therapy was associated with a 4.3-fold increase in theophylline clearance in a pediatric patient after approximately 4 weeks of concomitant therapy.<sup>6</sup> Theophylline is primarily metabolized by CYP1A2 and somewhat by CYP3A4. Both of these isoenzymes are induced by barbiturates.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Saccar CL, Danish M, Ragni MC, et al, “The Effects of Phenobarbital on Theophylline Disposition in Children With Asthma,” <i>J Allergy Clin Immunol</i>, 1985, 75:716-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4008801\">[PubMed 4008801]</a></p>\n<p>2. Landay RA, Gonzalez MA, and Taylor JC, “Effect of Phenobarbital on Theophylline Disposition,” <i>J Allergy Clin Immunol</i>, 1978, 62:27. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=659737\">[PubMed 659737]</a></p>\n<p>3. Piafsky KM, Sitar DS, and Ogilvie RI, “Effect of Phenobarbital on the Disposition of Intravenous Theophylline,” <i>Clin Pharmacol Ther</i>, 1977, 22:336. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=891099\">[PubMed 891099]</a></p>\n<p>4. Islam SI, Ali AS, Sheikh AA, et al, “Pharmacokinetics of Theophylline in Preterm Neonates During the First Month of Life,” <i>Saudi Med J</i>, 2004, 25(4):459-65. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15083216\">[PubMed 15083216]</a></p>\n<p>5. Dahlqvist R, Steiner E, Koike Y, et al, “Induction of Theophylline Metabolism by Pentobarbital,” <i>Ther Drug Monit</i>, 1989, 11:408-10. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2741188\">[PubMed 2741188]</a></p>\n<p>6. Paladino JA, Blumer NA, and Maddox RR, “Effect of Secobarbital on Theophylline Clearance,” <i>Ther Drug Monit</i>, 1983, 5:135-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6845397\">[PubMed 6845397]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3228":"<p><b>Title</b> Vitamin K Antagonists / Barbiturates</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Barbiturates may increase the metabolism of Vitamin K Antagonists. <b>Severity</b> Major <b>Onset</b> Delayed <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of oral anticoagulants if a barbiturate is initiated/dose increased (anticoagulant dose increases of 30% to 60% may be needed, depending on INR or PT results). Monitor for increased effects following discontinuation or dose reduction of a barbiturate. An increased frequency of INR/PT monitoring should be considered for the period immediately following barbiturate initiation/dosage changes.</p>\n<div>\n <p><b>Barbiturates Interacting Members</b> Amobarbital*, Butabarbital*, Butalbital, Methohexital, PENTobarbital, PHENobarbital*, Primidone, Secobarbital*, Thiopental</p>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Numerous case reports and small studies describe decreased concentrations/increased dose requirements of vitamin K antagonists during treatment with barbiturates, or increased concentrations/decreased dose requirements following barbiturate discontinuation.<sup>1,2,3,4,5,6,7,8,9,10,11</sup> Dosage increases of 30% to 60% are often required to maintain adequate treatment following barbiturate initiation.<br><br>The likely mechanism for this apparent interaction is induction of warfarin metabolism via CYP2C9, CYP3A4, and/or other enzymes. Phenobarbital is largely considered a strong inducer of several different drug metabolizing enzymes, though there is surprisingly limited study data to confirm these effects. Whether all barbiturates share similar potential to induce such metabolizing enzymes is uncertain. A study in rats found that phenobarbital increased the clearance of antipyrine (an indicator of general oxidative metabolism, as its metabolism is dependent on several different enzymes) by an average of 3.0-fold, while butalbital also increased antipyrine clearance, but only by 1.6-fold versus control.<sup>12</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Robinson DS, Sylwester D. Interaction of commonly prescribed drugs and warfarin. <i>Ann Intern Med</i>. 1970;72(6):853-856. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5448744\">[PubMed 5448744]</a></p>\n<p>2. Levy G, O'Reilly RA, Aggeler PM, Keech GM. Parmacokinetic analysis of the effect of barbiturate on the anticoagulant action of warfarin in man. <i>Clin Pharmacol Ther</i>. 1970;11(3):372-377. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5445741\">[PubMed 5445741]</a></p>\n<p>3. MacDonald MG, Robinson DS, Sylwester D, Jaffe JJ. The effects of phenobarbital, chloral betaine, and glutethimide administration on warfarin plasma levels and hypoprothrombinemic responese in man. <i>Clin Pharmacol Ther</i>. 1969;10(1):80-84. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5763659\">[PubMed 5763659]</a></p>\n<p>4. MacDonald MG, Robinson DS. Clinical observations of possible barbiturate interference with anticoagulation. <i>JAMA</i>. 1968;204(2):97-100. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5694725\">[PubMed 5694725]</a></p>\n<p>5. Udall JA. Clinical implications of warfarin interactions with five sedatives. <i>Am J Cardiol</i>. 1975;35(1):67-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1109248\">[PubMed 1109248]</a></p>\n<p>6. Breckenridge A, Orme ML, Davies L, Thorgeirsson SS, Davies DS. Dose-dependent enzyme induction. <i>Clin Pharmacol Ther</i>. 1973;14(4):514-520. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4723259\">[PubMed 4723259]</a></p>\n<p>7. Goss JE, Dickhaus DW. Increased bishydroxycoumarin requirements in patients receiving phenobarbital. <i>N Engl J Med</i>. 1965;273(20):1094-1095. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=158082\">[PubMed 158082]</a></p>\n<p>8. Cucinell SA, Odessky L, Weiss M, Dayton PG. The effect of chloral hydrate on bishydroxycoumarin metabolism; a fatal outcome. <i>JAMA</i>. 1966;197(5):366-368. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4161665\">[PubMed 4161665]</a></p>\n<p>9. O'Reilly RA, Trager WF, Motley CH, Howald W. Interaction of secobarbital with warfarin pseudoracemates. <i>Clin Pharmacol Ther</i>. 1980;28(2):187-195. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7398186\">[PubMed 7398186]</a></p>\n<p>10. Kroon C, de Boer A, Hoogkamer JF, et al. Detection of drug interactions with single dose acenocoumarol: new screening method? <i>Int J Clin Pharmacol Ther Toxicol</i>. 1990;28(8):355-360. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2272718\">[PubMed 2272718]</a></p>\n<p>11. Breckenridge A, Davies DS, Davies L, Orme M. Dose-dependent enzyme induction. <i>Br J Pharmacol</i>. 1973;47(3):616P-617P. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4730838\">[PubMed 4730838]</a></p>\n<p>12. Tse FL, Chang T, Jaffe JM. Effect of butalbital and phenobarbital pretreatment on antipyrine clearance in the rat. <i>Arch Int Pharmacodyn Ther</i>. 1986;279(2):181-194. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3963935\">[PubMed 3963935]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3230":"<p><b>Title</b> Alpha-/Beta-Agonists (Indirect-Acting) / Reverse Transcriptase Inhibitors (Nucleoside)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Reverse Transcriptase Inhibitors (Nucleoside) may enhance the hypertensive effect of Alpha-/Beta-Agonists (Indirect-Acting). <b>Severity</b> Major <b>Onset</b> Immediate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor for toxic effects of indirect-acting alpha-/beta-agonists (eg, hypertension) in patients receiving concomitant reverse transcriptase inhibitor (nucleoside) therapy.</p>\n<div>\n <p><b>Alpha-/Beta-Agonists (Indirect-Acting) Interacting Members</b> Amezinium, Ephedra, EPHEDrine (Nasal), EPHEDrine (Systemic), Pseudoephedrine</p>\n <p><b>Reverse Transcriptase Inhibitors (Nucleoside) Interacting Members</b> Abacavir, Adefovir, Clevudine, Didanosine, Emtricitabine, Entecavir, LamiVUDine*, Stavudine*, Zidovudine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Case report. A patient being treated with indinavir, lamivudine, and stavudine received a dose of phenylpropanolamine plus clemastine.<sup>1</sup> Within 6 hours she developed headache, difficulty breathing, chest tightness, increased blood pressure (220/120 mm Hg), and weakness in her left arm. The symptoms subsided within a few hours. Considering the phenylpropanolamine to be the likely culprit, it was noted that she had not experienced problems with the drug preantiretroviral therapy, nor during the year following the completion of the same therapy. A mechanism for this possible interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Khurana V, “Hypertensive Crisis Secondary to Phenylpropanolamine Interacting With Triple-Drug Therapy for HIV Prophylaxis,” <i>Am J Med</i>, 1999, 106:118. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10320127\">[PubMed 10320127]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3232":"<p><b>Title</b> Primidone / Phenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Phenytoin may increase the metabolism of Primidone. The ratio of primidone:phenobarbital is thus changed. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Though often used advantageously, monitor for increased serum concentrations of phenobarbital (a metabolite of primidone) during concomitant administration of phenytoin and primidone.</p> \n<p><b>Discussion</b> The serum phenobarbital:primidone ratio is significantly higher in patients receiving primidone plus phenytoin, than in patients receiving only primidone.<sup>1,2,3,4</sup> Primidone is partially metabolized to phenobarbital. Phenytoin apparently induces this conversion pathway. Phenytoin might also compete for sites of phenobarbital metabolism, thus reducing the elimination of the converted product. Though often used advantageously, this combination has resulted in phenobarbital toxicity.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Fincham RW, Schottelius DD, and Sahs AL, “The Influence of Diphenylhydantoin on Primidone Metabolism,” <i>Arch Neurol</i>, 1974, 30:259. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4812960\">[PubMed 4812960]</a></p>\n<p>2. Schmidt D, “The Effect of Phenytoin and Ethosuximide on Primidone Metabolism in Patients With Epilepsy,” <i>J Neurol</i>, 1975, 209:115. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=51048\">[PubMed 51048]</a></p>\n<p>3. Reynolds EJ, Fenton G, Fenwick P, et al, “Interaction of Phenytoin and Primidone,” <i>Br Med J</i>, 1975, 2:594. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1131627\">[PubMed 1131627]</a></p>\n<p>4. Gallagher BB, Baumel IP, Mattson RH, et al, “Primidone, Diphenylhydantoin and Phenobarbital. Aspects of Acute and Chronic Toxicity,” <i>Neurology</i>, 1973, 23:145-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4734509\">[PubMed 4734509]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3233":"<p><b>Title</b> Barbiturates / Pyridoxine</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: This interaction has only been suggested at high pyridoxine doses (80-200 mg/day).</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Pyridoxine may increase the metabolism of Barbiturates. Apparent in high pyridoxine doses (eg, 200 mg/day) <b>Severity</b> Moderate <b>Onset</b> Delayed <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased serum concentrations/effects of barbiturates in patients receiving concomitant high-dose pyridoxine (e.g. 80-200 mg/day). Typical multiple vitamin preparations are not likely to cause problems.</p>\n<div>\n <p><b>Barbiturates Interacting Members</b> Amobarbital, Butabarbital, Butalbital, Methohexital, PENTobarbital, PHENobarbital*, Primidone, Secobarbital, Thiopental</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Serum phenobarbital concentrations were approximately halved in 5 patients (also receiving chronic phenytoin therapy) following 4 weeks of concomitant therapy with pyridoxine (80-200 mg/day).<sup>1</sup> <br><br>The mechanism of this apparent interaction is unknown. The authors of the report suggest that pyridoxine might increase hepatic enzyme activity, and thus increase phenobarbital metabolism. The ability of pyridoxine doses found in typical multiple vitamin preparations to produce these same effects is unknown, but presumed doubtful.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Hansson O and Sillanpaa M, “Pyridoxine and Serum Concentrations of Phenytoin and Phenobarbitone,” <i>Lancet</i>, 1976, i:256. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=55569\">[PubMed 55569]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3234":"<p><b>Title</b> Phenytoin / Pyridoxine</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: This interaction has only been suggested at high pyridoxine doses (80-200 mg/day).</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Pyridoxine may increase the metabolism of Phenytoin. This is most apparent in high pyridoxine doses (e.g., 80 mg to 200 mg daily) <b>Severity</b> Moderate <b>Onset</b> Delayed <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased serum concentrations/effects of phenytoin in patients receiving concomitant high-dose pyridoxine (eg, 80-200 mg/day). Typical multiple vitamin preparations are not likely to cause problems.</p> \n<p><b>Discussion</b> Serum phenytoin concentrations were approximately halved in patients (also receiving chronic phenobarbital therapy) following 2-4 weeks of concomitant therapy with pyridoxine (80-200 mg/day).<sup>1</sup> The mechanism of this apparent interaction is unknown. The authors of the report suggest that pyridoxine might increase hepatic enzyme activity, and thus increase phenytoin metabolism. The ability of pyridoxine doses found in typical multiple vitamin preparations to produce these same effects is unknown, but presumed doubtful.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Hansson O and Sillanpaa M, “Pyridoxine and Serum Concentration of Phenytoin and Phenobarbitone,” <i>Lancet</i>, 1976, i:256. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=55569\">[PubMed 55569]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3237":"<p><b>Title</b> HMG-CoA Reductase Inhibitors (Statins) / Phenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Phenytoin may decrease the serum concentration of HMG-CoA Reductase Inhibitors (Statins). <b>Severity</b> Moderate <b>Onset</b> Delayed <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider avoiding the concomitant use of phenytoin and HMG-CoA reductase inhibitors. Monitor for decreased therapeutic effects of HMG-CoA reductase inhibitors if phenytoin is initiated/dose increased, or increased effects (possible toxicity) if phenytoin is discontinued/dose decreased. Red yeast rice contains lovastatin (possibly 2.4 mg per 600 mg of red yeast rice) and several other mevinic acid compounds.</p>\n<div>\n <p><b>HMG-CoA Reductase Inhibitors (Statins) Interacting Members</b> AtorvaSTATin*, Fluvastatin*, Lovastatin, Pravastatin, Red Yeast Rice, Simvastatin*<br><b>Exceptions</b> Pitavastatin, Rosuvastatin</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Case report. A simvastatin-stable patient (10 mg daily) experienced a 70% increase in total cholesterol following initiation of phenytoin (325 mg/day).<sup>1</sup> A fourfold simvastatin dosage increase resulted in better control, but still elevated cholesterol. Fluvastatin (40 mg/day) was unable to adequately control the patient's cholesterol. Better control was achieved on a reduced dosage of phenytoin (225 mg/day) plus atorvastatin (80 mg/day), and then later on atorvastatin without phenytoin. Phenytoin is a potent inducer of various CYP isoenzymes, and several HMG-CoA reductase inhibitors are substrates of these same isoenzymes. The result is increased metabolism of the antilipemic agents. Pravastatin is not significantly metabolized by CYP isoenzymes, but phenytoin may affect this agent via p-glycoprotein induction. Red yeast rice contains lovastatin (possibly 2.4 mg per 600 mg of red yeast rice) and several other mevinic acid compounds. Rosuvastatin does not appear to be affected by either CYP3A4 or p-glycoprotein.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Murphy MJ and Dominiczak MH, “Efficacy of Statin Therapy: Possible Effect of Phenytoin,” <i>Postgrad Med J</i>, 1999, 75:(884):359-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10435174\">[PubMed 10435174]</a></p>\n<p>2. Cooper KJ, Martin PD, Dane AL, et al, “Lack of Effect of Ketoconazole on the Pharmacokinetics of Rosuvastatin in Healthy Subjects,” <i>Br J Clin Pharmacol</i>, 2003, 55(1):94-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12534645\">[PubMed 12534645]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3239":"<p><b>Title</b> Trimethoprim / Phenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Trimethoprim may increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Trimethoprim. <b>Severity</b> Major <b>Onset</b> Delayed <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Consider alternatives to this combination when possible, to avoid potentially diminished trimethoprim efficacy and increased phenytoin concentrations/effects. The risk for a significant interaction is likely higher with the combination sulfamethoxazole/trimethoprim product as both components may increase phenytoin concentrations/effects. Monitor patients closely for both evidence of phenytoin toxicity and decreased trimethoprim effectiveness.</p> \n<p><b>Discussion</b> In a clinical study of healthy volunteers, administration of trimethoprim (320 mg/day for 7 days) together with a single intravenous dose of phenytoin was associated with an average 30% decrease in phenytoin clearance and a 51% increase phenytoin half-life.<sup>1</sup> Administration of the combination product sulfamethoxazole/trimethoprim (SMZ/TMP) with phenytoin was associated with a similar 27% decrease in phenytoin clearance, suggesting that trimethoprim was primarily responsible for observed interaction. Two case reports describe the development of symptoms of phenytoin toxicity in patients receiving SMZ/TMP.<sup>2,3</sup> Additionally, in a case control study of patients over 65 years old receiving phenytoin, recent use of SMZ/TMP increased the odds of phenytoin toxicity requiring hospitalization by approximately 2-fold (note that only around 2% of patients were exposed to the drug combination).<sup>4</sup><br><br>The suspected primary mechanism of interaction between these agents is trimethoprim inhibition of the CYP2C8- and CYP2C9-mediated phenytoin metabolism. Trimethoprim has been shown to be a relatively selective inhibitor of CYP2C8 at therapeutic concentrations, with some possible inhibition of CYP2C9 at higher concentrations.<sup>5</sup> CYP2C9 and CYP2C19 play relatively substantial roles in phenytoin metabolism, but CYP2C8 (along with other enzymes) also appear to contribute to phenytoin metabolism.<sup>6</sup> In addition, as a major inducer of drug metabolism, phenytoin may theoretically decrease trimethoprim systemic exposure via induction of its metabolism via CYP3A4 and/or CYP2C9.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Hansen JM, Kampmann JP, Siersbaek-Nielsen K, et al. The effect of different sulfonamides on phenytoin metabolism in man. <i>Acta Med Scand Suppl</i>. 1979;624:106-110. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=284708\">[PubMed 284708]</a></p>\n<p>2. Gillman MA, Sandyk R. Phenytoin toxicity and co-trimoxazole. <i>Ann Intern Med</i>. 1985;102(4):559. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3872091\">[PubMed 3872091]</a></p>\n<p>3. Wilcox JB. Phenytoin intoxication and cotrimoxazole. <i>N Z Med J</i>. 1981;94(692):235-236. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6975449\">[PubMed 6975449]</a></p>\n<p>4. Antoniou T, Gomes T, Mamdani MM, Juurlink DN. Trimethoprim/sulfamethoxazole-induced phenytoin toxicity in the elderly: a population-based study. <i>Br J Clin Pharmacol</i>. 2011;71(4):544-549. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21395647\">[PubMed 21395647]</a></p>\n<p>5. Wen X, Wang JS, Backman JT, Laitila J, Neuvonen PJ. Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively. <i>Drug Metab Dispos</i>. 2002;30(6):631-635. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12019187\">[PubMed 12019187]</a></p>\n<p>6. Komatsu T, Yamazaki H, Asahi S, et al. Formation of a dihydroxy metabolite of phenytoin in human liver microsomes/cytosol: roles of cytochromes P450 2C9, 2C19, and 3A4. <i>Drug Metab Dispos</i>. 2000;28(11):1361-1368. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11038165\">[PubMed 11038165]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3240":"<p><b>Title</b> Taxane Derivatives / Platinum Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Platinum Derivatives may enhance the myelosuppressive effect of Taxane Derivatives. Administer Taxane derivative before Platinum derivative when given as sequential infusions to limit toxicity. <b>Severity</b> Major <b>Onset</b> Rapid (Sequence Important) <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Administer paclitaxel before cisplatin, when given as sequential infusions, to limit toxicity. Problems associated with other taxane/platinum combinations are possible, although unsubstantiated. Administering the taxane derivative before the platinum derivative seems prudent.</p>\n<div>\n <p><b>Platinum Derivatives Interacting Members</b> CARBOplatin, CISplatin*, Oxaliplatin</p>\n <p><b>Taxane Derivatives Interacting Members</b> Cabazitaxel, DOCEtaxel, PACLitaxel (Conventional)*, PACLitaxel (Protein Bound)</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The manufacturer of paclitaxel states the following: “In a Phase I trial using escalating doses of [paclitaxel] (110-200 mg/m<sup>2</sup>) and cisplatin (50 or 75 mg/m<sup>2</sup>) given as sequential infusions, myelosuppression was more profound when [paclitaxel] was given after cisplatin than with the alternate sequence (ie, [paclitaxel] before cisplatin).\"<sup>1</sup> Pharmacokinetic data demonstrate a decrease in paclitaxel clearance of approximately 25% to 33% when paclitaxel is administered following cisplatin.<sup>1,2</sup><br><br>Limited pharmacokinetic and pharmacodynamic studies with carboplatin and paclitaxel do not demonstrate negative effects on either.<sup>3,4,5</sup> In fact, attenuation of the severity of thrombocytopenia has been noted with combination therapy.<sup>3,4</sup> Cisplatin does not appear to affect the metabolism of either docetaxel or paclitaxel.<sup>6</sup> A subsequent study evaluationg the degree of neutropenia produced by the combination of paclitaxel and carboplatin, administered in either order, showed no effect of the sequence of infusion on nadirs.<sup>7</sup> Oxaliplatin (2-hour infusion) clearance was increased in head and neck cancer patients when administered before an infusion (1-hour) of paclitaxel.<sup>8</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Taxol [package insert]. Princeton, NJ: Bristol-Myers Squibb Oncology, 2000.</p>\n<p>2. Rowinsky EK, Gilbert M, McGuire WP, et al, “Sequences of Taxol and Cisplatin: A Phase I and Pharmacologic Study,” <i>J Clin Oncol</i>, 1991, 9(9):1962-1703. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1678780\">[PubMed 1678780]</a></p>\n<p>3. Obasaju CK, Johnson SW, Rogatko A, et al, “Evaluation of Carboplatin Pharmacokinetics in the Absence and Presence of Paclitaxel,” <i>Clin Cancer Res</i>, 1996, 2(3):549-52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9816202\">[PubMed 9816202]</a></p>\n<p>4. Huizing MT, Giaccone G, van Warmerdam LJ, et al, “Pharmacokinetics of Paclitaxel and Carboplatin in a Dose-Escalating and Dose-Sequencing Study in Patients With Non-Small-Cell Lung Cancer: The European Cancer Centre,” <i>J Clin Oncol</i>, 1997, 15(1):317-29. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8996159\">[PubMed 8996159]</a></p>\n<p>5. Belani CP, Kearns CM, Zuhowski EG, et al, “Phase I Trial, Including Pharmacokinetic and Pharmacodynamic Correlations, of Combination Paclitaxel and Carboplatin in Patients With Metastatic Non-Small-Cell Lung Cancer,” <i>J Clin Oncol</i>, 1999, 17(2):676-84. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10080614\">[PubMed 10080614]</a></p>\n<p>6. Royer I, Monsarrat B, Sonnier M, et al, “Metabolism of Docetaxel by Human Cytochromes P450: Interactions With Paclitaxel and Other Antineoplastic Drugs,” <i>Cancer Res</i>, 1996, 56(1):58-65. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8548776\">[PubMed 8548776]</a></p>\n<p>7. Markman M, Elson P, Kulp B, et al, “Carboplatin Plus Paclitaxel Combination Chemotherapy: Impact of Sequence of Drug Administration on Treatment-Induced Neutropenia,” <i>Gynecol Oncol</i>, 2003, 91(1):118-22. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14529670\">[PubMed 14529670]</a></p>\n<p>8. Liu J, Kraut E, Bender J, et al, “Pharmacokinetics of Oxaliplatin (NSC 266046) Alone and in Combination With Paclitaxel in Cancer Patients,” <i>Cancer Chemother Pharmacol</i>, 2002, 49(5):367-74. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11976830\">[PubMed 11976830]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3241":"<p><b>Title</b> Teniposide / Phenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Phenytoin may decrease the serum concentration of Teniposide. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Consider alternatives to combined treatment with phenytoin and teniposide due to the potential for decreased teniposide concentrations. If the combination cannot be avoided, monitor teniposide response closely.</p> \n<p><b>Discussion</b> The clearance of teniposide was 2.5-fold higher in 6 children with acute lymphocytic leukemia (ALL) receiving phenytoin or phenobarbital than in matched controls.<sup>1</sup> In a retrospective review of children with ALL treated with teniposide, concomitant treatment with phenytoin or phenobarbital (with or without other enzyme-inducing medications) was associated with worse event-free survival, hematologic relapse, and CNS relapse in patients with B-cell lineage malignancies.<sup>2</sup> Additionally, a review of a subset of patients who had teniposide clearance estimates showed greater clearance in patients receiving phenytoin or phenobarbital.<br><br>The mechanism of this interaction has not been investigated. Phenytoin induction of CYP3A mediated teniposide metabolism likely contributes.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Baker DK, Relling MV, Pui CH, et al, “Increased Teniposide Clearance With Concomitant Anticonvulsant Therapy,” <i>J Clin Oncol</i>, 1992, 10(2):311-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1732431\">[PubMed 1732431]</a></p>\n<p>2. Relling MV, Pui CH, Sandlund JT, et al, “Adverse Effect of Anticonvulsants on Efficacy of Chemotherapy for Acute Lymphoblastic Leukaemia,” <i>Lancet</i>, 2000, 356(9226):285-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11071183\">[PubMed 11071183]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3244":"<p><b>Title</b> Teniposide / Barbiturates</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Barbiturates may decrease the serum concentration of Teniposide. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Consider alternatives to combined treatment with barbiturates and teniposide due to the potential for decreased teniposide concentrations. If the combination cannot be avoided, monitor teniposide response closely.</p>\n<div>\n <p><b>Barbiturates Interacting Members</b> Amobarbital, Butabarbital, Butalbital, Methohexital, PENTobarbital, PHENobarbital*, Primidone, Secobarbital, Thiopental</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The clearance of teniposide was 2.5-fold higher in 6 children with acute lymphocytic leukemia (ALL) receiving phenytoin or phenobarbital than in matched controls.<sup>1</sup> In a retrospective review of children with ALL treated with teniposide, concomitant treatment with phenytoin or phenobarbital (with or without other enzyme-inducing medications) was associated with worse event-free survival, hematologic relapse, and CNS relapse in patients with B-cell lineage malignancies.<sup>2</sup> Additionally, a review of a subset of patients who had teniposide clearance estimates showed greater clearance in patients receiving phenytoin or phenobarbital.<br><br>The mechanism of this interaction has not been investigated. Phenobarbital induction of CYP3A mediated teniposide metabolism likely contributes.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Baker DK, Relling MV, Pui CH, et al, “Increased Teniposide Clearance With Concomitant Anticonvulsant Therapy,” <i>J Clin Oncol</i>, 1992, 10(2):311-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1732431\">[PubMed 1732431]</a></p>\n<p>2. Relling MV, Pui CH, Sandlund JT, et al, “Adverse Effect of Anticonvulsants on Efficacy of Chemotherapy for Acute Lymphoblastic Leukaemia,” <i>Lancet</i>, 2000, 356(9226):285-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11071183\">[PubMed 11071183]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3245":"<p><b>Title</b> Phenytoin / Theophylline Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Phenytoin may decrease the serum concentration of Theophylline Derivatives. Theophylline Derivatives may decrease the serum concentration of Phenytoin. <b>Severity</b> Major <b>Onset</b> Delayed <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Seek alternatives to this combination when possible. If these agents are used together, monitor closely for decreased serum concentrations/therapeutic effects of phenytoin or theophylline if the other agent is initiated/dose increased, or increased concentrations/toxic effects if the other agent is discontinued/dose decreased.</p>\n<div>\n <p><b>Theophylline Derivatives Interacting Members</b> Acebrophylline, Aminophylline*, Theophylline*<br><b>Exception</b> Dyphylline</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The half-life of theophylline (administered as aminophylline 5.6 mg/kg IV over 30 minutes) was decreased by approximately 50% in 10 normal subjects when administered following a 10-day (minimum) course of phenytoin (300-400 mg/day).<sup>1</sup> Other reports demonstrate increased clearance of theophylline in both normal subjects and patients during concomitant phenytoin therapy.<sup>2,3,4</sup> This interaction is likely due to the ability of phenytoin to induce CYP3A4 isoenzymes, and thus increase theophylline metabolism.<br><br>Mean serum phenytoin concentrations increased by 30% in 14 normal subjects following the discontinuation of theophylline dosing.<sup>5</sup> Theophylline and phenytoin had been coadministered for approximately 2 weeks. The mechanism of this interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Marquis JF, Carruthers SG, Spense JD, et al, “Phenytoin-Theophylline Interaction,” <i>N Engl J Med</i>, 1982, 307:1189-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7121545\">[PubMed 7121545]</a></p>\n<p>2. Miller M, Cosgriff J, Kwong T, et al, “Influence of Phenytoin on Theophylline Clearance,” <i>Clin Pharmacol Ther</i>, 1984, 35:666-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6713777\">[PubMed 6713777]</a></p>\n<p>3. Sklar SJ and Wagner JC, “Enhanced Theophylline Clearance Secondary to Phenytoin Therapy,” <i>Drug Intell Clin Pharm</i>, 1985, 19:34-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3967572\">[PubMed 3967572]</a></p>\n<p>4. Reed RC and Schwartz HJ, “Phenytoin-Theophylline-Quinidine Interaction,” <i>N Engl J Med</i>, 1983, 308:724-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6828116\">[PubMed 6828116]</a></p>\n<p>5. Taylor JW, Hendeles L, Weinberger M, et al, “The Interaction of Phenytoin and Theophylline,” <i>Drug Intell Clin Pharm</i>, 1980, 14:638.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3246":"<p><b>Title</b> Thyroid Products / Phenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Phenytoin may decrease the serum concentration of Thyroid Products. Phenytoin may also displace thyroid hormones from protein binding sites. <b>Severity</b> Moderate <b>Onset</b> Delayed <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased serum concentrations/therapeutic effects of thyroid products if phenytoin is initiated/dose increased. TSH may be elevated. Other measures of thyroid function (e.g., T<sub>4</sub>,T<sub>3</sub>) may be variably altered. Also note that thyroid concentrations/effects may be increased following phenytoin dose reduction or discontinuation.</p>\n<div>\n <p><b>Thyroid Products Interacting Members</b> Levothyroxine*, Liothyronine, Liotrix, Thyroid, Desiccated</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> A study in which six levothyroxine-stable female patients were administered phenytoin (350 mg/day) demonstrated a complex interaction between phenytoin and levothyroxine.<sup>1</sup> They noted a decrease in the amount of levothyroxine absorbed across the gut wall and an increase in nondeionative metabolism of levothyroxine. Although the fraction of T<sub>4</sub> converted to T<sub>3</sub> increased and the fraction of T<sub>4</sub> converted to rT<sub>3</sub> decreased, there was no change in the absolute amount of T<sub>3</sub> produced.<sup>1</sup> A case report describes a levothyroxine-stable patient who became hypothyroid after initiating phenytoin therapy (300 mg/day).<sup>2</sup> Subsequent dechallenge and rechallenge with phenytoin confirmed its role in the interaction.<br><br>Phenytoin likely increases the cytochrome P450 (CYP)-mediated metabolism of the thyroid product. In addition, phenytoin may displace the thyroid product from its protein binding site, presenting more for CYP metabolism.<sup>3</sup> A study in the rat indicates that while the free fraction of T<sub>4</sub> is elevated in vitro, there is no significant change in vivo, likely due to a phenytoin-related alteration in the protein binding of thyroid hormone.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Faber J, Lumholtz IB, Kirkegaard C, et al, “The Effects of Phenytoin (Diphenylhydantoin) on the Extrathyroidal Turnover of Thyroxine, 3,5,3’-Triiodothyronine, 3,3’,5’-Triiodothyronine, and 3’,5’-Diiodothyronine in Man,” <i>J Clin Endocrinol Metab</i>, 1985, 61(6):1093-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4055984\">[PubMed 4055984]</a></p>\n<p>2. Blackshear JL, Schultz AL, Napier JS, et al, “Thyroxine Replacement Requirements in Hypothyroid Patients Receiving Phenytoin,” Ann Intern Med, 1983, 99:341. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6614682\">[PubMed 6614682]</a></p>\n<p>3. Franklyn JA, Sheppard MC, and Ramsden DB, “Measurement of Free Thyroid Hormones in Patients on Long-Term Phenytoin Therapy,” Eur J Clin Pharmacol, 1984, 26:633-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6468481\">[PubMed 6468481]</a></p>\n<p>4. Goussis OS, Theodoropoulos TJ, “Dilantin and Salicylate Effects on Hepatic Thyroxine Bio-availability and Dialyzable Thyroxine,” <i>Horm Meta Res</i>, 1990, 22(6):342-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2379917\">[PubMed 2379917]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3247":"<p><b>Title</b> Phenytoin / Ticlopidine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ticlopidine may increase the serum concentration of Phenytoin. <b>Severity</b> Moderate <b>Onset</b> Delayed <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor closely for increased serum concentration/systemic effects of phenytoin following ticlopidine initiation/dose increase, and decreased concentration/effects following ticlopidine discontinuation/dose decrease.</p> \n<p><b>Discussion</b> Several published case reports describe 2-3 fold increases in serum phenytoin concentrations occurring within 1-6 weeks of initiating ticlopidine therapy.<sup>1,2,3,4,5</sup> All increases were associated with signs and symptoms consistent with phenytoin toxicity. Reductions in phenytoin dosage proved effective in managing the apparent interactions. Dechallenge and rechallenge with ticlopidine provided additional evidence of an interaction in two cases.<sup>4,5</sup> Additionally, in a clinical study of 6 phenytoin-treated patients, coadministration of ticlopidine (250 mg twice daily) significantly decreased phenytoin clearance (as reflected by an approximate doubling of the estimated Michaelis-Menten constant).<sup>6</sup><br><br>The suspected primary mechanism leading to the above affects is ticlopidine competitive inhibition of enzymes mediating phenytoin metabolism (primarily CYP2C19, possibly 2C9 as well).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Donahue SR, Flockhart DA, Abernethy DR, et al, “Ticlopidine Inhibition of Phenytoin Metabolism Mediated by Potent Inhibition of CYP2C19,” <i>Clin Pharmacol Ther</i>, 1997, 62:572-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9390115\">[PubMed 9390115]</a></p>\n<p>2. Privitera M and Welty TE, “Acute Phenytoin Toxicity Followed by Seizure Breakthrough From a Ticlopidine-Phenytoin Interaction,” <i>Arch Neurol</i>, 1996, 53:1191-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8912496\">[PubMed 8912496]</a></p>\n<p>3. Rindone JP and Bryan G, “Phenytoin Toxicity Associated With Ticlopidine Administration,” <i>Arch Intern Med</i>, 1996, 156:1113. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8639000\">[PubMed 8639000]</a></p>\n<p>4. Riva R, Cerullo A, Albani F, et al, “Ticlopidine Impairs Phenytoin Clearance: A Case Report,” <i>Neurology</i>, 1996, 46:1172. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8780118\">[PubMed 8780118]</a></p>\n<p>5. Klaassen SL, “Ticlopidine-Induced Phenytoin Toxicity,” <i>Ann Pharmacother</i>, 1998, 32(12):1295-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9876809\">[PubMed 9876809]</a></p>\n<p>6. Donahue S, Flockhart DA and Abernethy DR, “Ticlopidine Inhibits Phenytoin Clearance,” <i>Clin Pharmacol Ther</i>, 1999, 66(6):563-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10613611\">[PubMed 10613611]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3249":"<p><b>Title</b> Phenytoin / Vigabatrin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Vigabatrin may decrease the serum concentration of Phenytoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for decreased serum concentrations/therapeutic effects of phenytoin with concurrent vigabatrin.</p> \n<p><b>Discussion</b> Several studies have shown 20% to 30% decreases in serum phenytoin concentrations in patients receiving vigabatrin.<sup>1,2,3,4,5,6</sup> At times, this decrease results in subtherapeutic serum phenytoin concentrations. The mechanism of this interaction appears to be increased phenytoin metabolism via vigabatrin-mediated CYP2C9 induction.<sup>7</sup> Further, one report using both IV and oral phenytoin showed little difference in effect between the two, supporting that vigabatrin does not likely affect phenytoin absorption (at least as its primary effect).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Rimmer EM and Richens A, “Double-Blind Study of Gamma-Vinyl GABA in Patients With Refractory Epilepsy,” <i>Lancet</i>, 1984, i:189-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6141335\">[PubMed 6141335]</a></p>\n<p>2. Gatti G, Bartoli A, Marchiselli R, et al, “Vigabatrin-Induced Decrease in Serum Phenytoin Concentration Does Not Involve a Change in Phenytoin Bioavailability,” <i>Br J Clin Pharmacol</i>, 1993, 36:603-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12959280\">[PubMed 12959280]</a></p>\n<p>3. Browne TR, Mattson RH, Penry JK, et al, “A Multicentre Study of Vigabatrin for Drug-Resistant Epilepsy,” <i>Br J Clin Pharmacol</i>, 1989, 95-100S. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2667606\">[PubMed 2667606]</a></p>\n<p>4. Rimmer EM and Richens A, “Interaction Between Vigabatrin and Phenytoin,” <i>Br J Clin Pharmacol</i>, 1989, 27:27-33S. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2757906\">[PubMed 2757906]</a></p>\n<p>5. Browne TR, Mattson RH, Penry JK, et al, “Vigabatrin for Refractory Complex Partial Seizures; Multicenter Single-Blind Study With Long-Term Follow Up,” <i>Neurology</i>, 1987, 37:184-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3808298\">[PubMed 3808298]</a></p>\n<p>6. Tassinari CA, Michelucci R, Ambrosetto G, et al, “Double-Blind Study of Vigabatrin in the Treatment of Drug-Resistant Epilepsy,” <i>Arch Neurol</i>, 1987, 44:907-10. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2887152\">[PubMed 2887152]</a></p>\n<p>7. Prescribing information. Sabril (vigabatrin). Deerfield, IL: Lundbeck Inc., August 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3250":"<p><b>Title</b> Vitamin K Antagonists / Phenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Phenytoin may enhance the anticoagulant effect of Vitamin K Antagonists. Vitamin K Antagonists may increase the serum concentration of Phenytoin. <b>Severity</b> Major <b>Onset</b> Delayed <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Anticoagulant dose adjustment will likely be necessary when phenytoin is initiated or discontinued. Monitor anticoagulant status (i.e., INR) and for signs/symptoms of bleeding whenever this combination is used. Monitor for increased effects of warfarin, and significantly decreased effects of dicumarol, if phenytoin is initiated/dose increased, and the opposite effects if phenytoin is discontinued/dose decreased. Monitor for increased serum concentrations/toxic effects of phenytoin if a coumarin derivative is initiated/dose increased, or decreased serum concentrations/effects if a vitamin K antagonist is discontinued/dose decreased. These effects would most likely manifest during the first 1-2 months of therapy.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> PHENYTOIN IMPACT ON VITAMIN K ANTAGONISTS: One case report describes a 52% increase in prothrombin time (PT) in a warfarin-treated patient within a month of initiating phenytoin (300 mg/day) [this increase occurred in spite of a 22% decrease in warfarin dosage].<sup>1</sup> Another report describes the initial development of increased anticoagulant effects in a warfarin-treated patient and subsequent decreased anticoagulant effects (after approximately 6 days).<sup>2</sup> Several additional cases of increased/altered warfarin and acenocoumarol effects have been reported.<sup>3,4,5,6,7,8</sup> Significant decreases in the effects (commensurate with up to 75% decreases in serum concentrations) of dicumarol have been reported to occur within 1-2 months of initiating phenytoin therapy.<sup>9</sup> Several weeks can be required (post-phenytoin initiation) for dicumarol effects to normalize.<br><br>The exact mechanism(s) of these contrasting interactions is unclear. Phenytoin may cause an initial displacement of warfarin from protein binding sites, resulting in a transient increase in anticoagulant effects. These increased effects may then eventually be overcome by phenytoin induction of CYP isoenzymes involved in warfarin metabolism. As such, warfarin (aside from an initial monitoring period) would not likely cause significant clinical concern. Dicumarol, on the other hand, appears significantly affected by phenytoin. In addition, phenytoin may exert an independent effect on clotting factor concentrations and/or coagulation.<br><br>VITAMIN K ANTAGONIST IMPACT ON PHENYTOIN: Serum phenytoin concentrations (based on 300 mg/day) increased more than 2-fold in six healthy subjects within a week of initiating dicumarol.<sup>10</sup> A case report describes the development of phenytoin toxicity within a few days of initiating warfarin therapy.<sup>11</sup><br><br>The mechanism of this form of a phenytoin-vitamin K antagonist interaction is unclear. Dicumarol/warfarin may inhibit CYP2C9-mediated phenytoin metabolism.<br><br>Considering available data, it would appear as though warfarin would be a safer anticoagulant than dicumarol in phenytoin-treated patients.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Nappi JM, “Warfarin and Phenytoin Interaction,” <i>Ann Intern Med</i>, 1979, 90:852. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=434697\">[PubMed 434697]</a></p>\n<p>2. Levine M and Sheppard I, “Biphasic Interaction of Phenytoin and Warfarin,” <i>Clin Pharm</i>, 1984, 3:200-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6723231\">[PubMed 6723231]</a></p>\n<p>3. Koch-Weser J, “Haemorrhagic Reactions and Drug Interactions in 500 Warfarin Treated Patients,” <i>Clin Pharmacol Ther</i>, 1973, 14:139.</p>\n<p>4. Taylor JW, Alexander B, and Lyon LW, “A Comparative Evaluation of Oral Anticoagulant-Phenytoin Interactions,” <i>Drug Intell Clin Pharm</i>, 1980, 14:669-73.</p>\n<p>5. Abad-Santos F, Carcas AJ, F-Capitan C, et al, “Retroperitoneal Haematoma in a Patient Treated with Acenocoumarol, Phenytoin and Paroxetine,” <i>Clin Lab Haematol</i>, 1995, 17(2):195-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8536426\">[PubMed 8536426]</a></p>\n<p>6. Hassan Y, Awaisu A, Aziz NA, et al, “The Complexity of Achieving Anticoagulation Control in the Face of Warfarin-Phenytoin Interaction: An Asian Case Report,” <i>Pharm World Sci</i>, 2005, 27(1):16-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15861930\">[PubMed 15861930]</a></p>\n<p>7. Meisheri YV, “Simultaneous Phenytoin and Warfarin Toxicity on Chronic Concomitant Therapy,” <i>J Assoc Physicians India</i>, 1996, 44(9):661-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9251383\">[PubMed 9251383]</a></p>\n<p>8. Panegyres PK, Rischbieth RH, “Fatal Phenytoin Warfarin Interaction,” <i>Postgrad Med J</i>, 1991, 67(783):98. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2057444\">[PubMed 2057444]</a></p>\n<p>9. Hansen JM, Siersbaek-Nielsen K, Kristensen M, et al, “Effect of Diphenylhydantoin on the Metabolism of Dicoumarol in Man,” <i>Acta Med Scand</i>, 1971, 189:15. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4107730\">[PubMed 4107730]</a></p>\n<p>10. Hansen JM, Kristensen M, Skovsted L, et al, “Dicoumarol Induced Diphenylhydantoin Intoxication,” <i>Lancet</i>, 1966, ii:265. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4161425\">[PubMed 4161425]</a></p>\n<p>11. Rothermich NO, “Diphenylhydantoin Intoxication,” <i>Lancet</i>, 1966, ii:640.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3251":"<p><b>Title</b> Potassium-Sparing Diuretics / Potassium Salts</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Potassium Salts may enhance the hyperkalemic effect of Potassium-Sparing Diuretics. <b>Severity</b> Major <b>Onset</b> Delayed <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concomitant use of a potassium-sparing diuretic and a potassium salt should be avoided except in cases of significant hypokalemia, and only if serum potassium concentrations can be closely monitored. Also monitor for other evidence of hyperkalemia (e.g., muscular weakness, fatigue, arrhythmias, bradycardia) during concomitant use of these products. Patients with renal impairment, elevated serum potassium concentrations, and/or receiving medications that may increase serum potassium concentrations (e.g., ACE inhibitors, angiotensin receptor blockers) may be at increased risk of these adverse effects.</p>\n<div>\n <p><b>Potassium Salts Interacting Members</b> Potassium Acetate, Potassium Chloride*, Potassium Citrate, Potassium Gluconate, Potassium Iodate, Potassium Iodide, Potassium Phosphate</p>\n <p><b>Potassium-Sparing Diuretics Interacting Members</b> AMILoride, Eplerenone, Spironolactone*, Triamterene*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The incidence of hyperkalemia was increased approximately threefold in patients receiving spironolactone plus potassium chloride versus those receiving spironolactone alone.<sup>1</sup> The incidence was increased approximately sevenfold if the patient was receiving potassium chloride and also had azotemia (total incidence of 42% in this selected population). The incidence of hyperkalemia was approximately 50% in a retrospective review of 25 patients receiving both spironolactone and a potassium supplement.<sup>2</sup> Case reports of morbidity-associated hyperkalemia have been reported when using either spironolactone or triamterene with a potassium supplement/potassium-containing salt substitutes.<sup>3,4,5,6,7</sup> The effects of potassium-sparing diuretics and potassium supplementation are additive.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Greenblatt DJ and Koch-Weser J, “Adverse Reactions to Spironolactone. A Report From the Boston Collaborative Drug Surveillance Program,” <i>Clin Pharmacol Ther</i>, 1973, 14:136-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4740303\">[PubMed 4740303]</a></p>\n<p>2. Simborg DN, “Medication Prescribing on a University Medical Service - The Incidence of Drug Combinations With Potential Adverse Interactions,” <i>Johns Hopkins Med J</i>, 1976, 139:23. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=948149\">[PubMed 948149]</a></p>\n<p>3. Mashford ML and Robertson MB, “Spironolactone and Ammonium and Potassium Chloride,” <i>BMJ</i>, 1972, 4:298-9 (letter). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5083905\">[PubMed 5083905]</a></p>\n<p>4. Kalbian VV, “Iatrogenic Hyperkalemic Paralysis With Electrocardiographic Changes,” <i>South Med J</i>, 1974, 67:342. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4814187\">[PubMed 4814187]</a></p>\n<p>5. O’Reilly MV, Murnaghan DP, and Williams MB, “Transvenous Pacemaker Failure Induced by Hyperkalemia,” <i>JAMA</i>, 1974, 228:336-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4406078\">[PubMed 4406078]</a></p>\n<p>6. McCaughan D, “Hazards of Nonprescription Potassium Supplements,” <i>Lancet</i>, 1984, i:513-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6142238\">[PubMed 6142238]</a></p>\n<p>7. Yap V, Patel A, and Thomsen J, “Hyperkalemia With Cardiac Arrhythmia. Induction by Salt Substitutes, Spironolactone and Azotemia,” <i>JAMA</i>, 1976, 236:2775. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1036572\">[PubMed 1036572]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3253":"<p><b>Title</b> Thiopental / Probenecid</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Probenecid may enhance the adverse/toxic effect of Thiopental. Specifically, anesthetic potency and duration may be enhanced. <b>Severity</b> Moderate <b>Onset</b> Rapid <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor for increased magnitude and duration of pharmacologic effect of thiopental in patients receiving concomitant probenecid.</p> \n<p><b>Discussion</b> Clinical studies have shown increased potency and duration of thiopental-induced anesthesia in patients receiving probenecid.<sup>1,2</sup> <br><br>The mechanism of this interaction is unknown. Based on a study in rats, CNS penetration of thiopental may be enhanced by the presence of probenecid,<sup>3</sup> although no studies have been conducted to further clarify this mechanism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kaukinen S, Eerola M, and Ylitalo P, “Prolongation of Thiopentone Anaesthesia by Probenecid,” <i>Br J Anaesth</i>, 1980, 52:603-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7000105\">[PubMed 7000105]</a></p>\n<p>2. Dundee JW, Halliday NJ and McMurray TJ, “Aspirin and Probenecid Pretreatment Influences the Potency of Thiopentone and the Onset of Action of Midazolam,” <i>Eur J Anaesthesiol</i>, 1986, 3(3):247-51. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3780693\">[PubMed 3780693]</a></p>\n<p>3. Bolander HG and Wahlstrom G, “Interaction Between Probenecid and Two Lipid-Soluble Barbiturates in the Rat,” <i>Neuropharmacology</i>, 1984, 23(8):977-81. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6483121\">[PubMed 6483121]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3254":"<p><b>Title</b> Zidovudine / Probenecid</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Probenecid may decrease the metabolism of Zidovudine. <b>Severity</b> Moderate <b>Onset</b> Rapid <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for increased toxic effects of zidovudine if probenecid is initiated/dose increased, or decreased effects if probenecid is discontinued/dose decreased. A reduced dose of zidovudine may be warranted (eg, 50% reduction on the day of cidofovir administration during concomitant cidofovir, probenecid, and zidovudine therapy).<sup>1</sup></p> \n<p><b>Discussion</b> The AUC of zidovudine increased an average of 80% in 12 patients (AIDS or AIDS-related complex) when coadministered with probenecid (500 mg every 8 hours) for 3 days.<sup>2</sup> Similar pharmacokinetic changes have been reported elsewhere.<sup>3,4</sup> The incidence of zidovudine-associated adverse effects (eg, rash) appears to be increased by this combination of drugs.<sup>4</sup> The mechanism of this interaction seems related to the ability of probenecid to reduce the metabolism (glucuronidation) of zidovudine in the liver.<sup>2,4,6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Vistide [package insert]. Foster City, CA: Gilead Sciences, Inc, 2000.</p>\n<p>2. Kornhauser DM, Petty BG, Hendrix CW, et al, “Probenecid and Zidovudine Metabolism,” <i>Lancet</i>, 1989, 2:473-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2570186\">[PubMed 2570186]</a></p>\n<p>3. de Miranda P, Good SS, Yarchoan R, et al, “Alteration of Zidovudine Pharmacokinetics by Probenecid in Patients With AIDS or AIDS-Related Complex,” <i>Clin Pharmacol Ther</i>, 1989, 46:494-500. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2582706\">[PubMed 2582706]</a></p>\n<p>4. Campion JJ, Bawdon RE, Baskin LB, et al, “Effect of Probenecid on the Pharmacokinetics of Zidovudine and Zidovudine Glucuronide,” <i>Pharmacotherapy</i>, 1990, 10:235.</p>\n<p>5. Petty BG, Kornhauser DM, and Lietman PS, “Zidovudine with Probenecid: A Warning,” <i>Lancet</i>, 1990, 1:1044-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1970102\">[PubMed 1970102]</a></p>\n<p>6. Sim SM, Back DJ, and Breckenridge AM, “The Effect of Various Drugs on the Glucuronidation of Zidovudine (Azidothymidine: AZT) by Human Liver Microsomes,” <i>Br J Clin Pharmacol</i>, 1991, 32:17-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1909542\">[PubMed 1909542]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3256":"<p><b>Title</b> Procainamide / Trimethoprim</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Trimethoprim may increase serum concentrations of the active metabolite(s) of Procainamide. Trimethoprim may increase the serum concentration of Procainamide. <b>Severity</b> Moderate <b>Onset</b> Rapid <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Consider alternatives to trimethoprim-containing regimens to avoid this interaction. Monitor for increased toxic effects (QTc intervals, EKG, serum drug concentrations) of procainamide if trimethoprim is initiated/dose increased, or decreased effects if trimethoprim is discontinued/dose decreased.</p> \n<p><b>Discussion</b> The clearance of procainamide and N-acetyl procainamide (NAPA) (given 500 mg sustained release procainamide every 6 hours) was decreased 42% and 13%, respectively, in 8 healthy subjects when administered with trimethoprim (200 mg/day) for 3 days.<sup>1,2</sup> The 0-12 hour AUC of procainamide and NAPA were each increased more than 50% with small but significant increases in the QTc. A placebo-controlled study with 10 healthy males found a decreased clearance of procainamide and NAPA by 46% and 26% respectively when administered with trimethoprim (100 mg twice daily for two days followed by 200 mg twice daily administered with procainamide 1 gram).<sup>3</sup> The AUC was increased by 39% and 27% procainamide and NAPA, respectively. The mean QTc interval following procainamide administration with trimethoprim was 0.43 +/- 0.03 seconds as compared to 0.40 +/- 0.02 seconds with placebo. The mechanism of this interaction is likely due to inhibition of active renal secretion of procainamide by trimethoprim.<sup>4,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Kosoglou T, Rocci ML, and Vlasses PH, “Evaluation of Trimethoprim/Procainamide Interaction at Steady-State in Normal Volunteers,” <i>Clin Pharmacol Ther</i>, 1988, 43:131.</p>\n<p>2. Kosoglou T, Rocci ML, and Vlasses PH, “Trimethoprim Alters the Disposition of Procainamide and N-Acetylprocainamide,” <i>Clin Pharmacol Ther</i>, 1988, 44:467-77. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2458879\">[PubMed 2458879]</a></p>\n<p>3. Vlasses PH, Kosoglou T, Chase SL, et al, “Trimethoprim Inhibition of the Renal Clearance of Procainamide and N-Acetylprocainamide,” <i>Arch Intern Med</i>, 1989, 149:1350-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2471472\">[PubMed 2471472]</a></p>\n<p>4. Trujillo TC, Nolan PE, “Antiarrhythmic Agents: Drug Interactions of Clinical Significance,” <i>Drug Saf</i>, 2000, 23(6):509-32. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11144659\">[PubMed 11144659]</a></p>\n<p>5. Somogyi A, “Renal Transport of Drugs: Specificity and Molecular Mechanisms,” <i>Clin Exp Pharmacol Physiol</i>, 1996, 23(10-11):986-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8911747\">[PubMed 8911747]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3258":"<p><b>Title</b> Theophylline Derivatives / Propafenone</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Propafenone may increase the serum concentration of Theophylline Derivatives. <b>Severity</b> Moderate <b>Onset</b> Delayed <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased serum concentrations/toxic effects of theophylline derivatives if propafenone is initiated/dose increased, or decreased serum concentrations/effects if propafenone is discontinued/dose decreased.</p>\n<div>\n <p><b>Theophylline Derivatives Interacting Members</b> Acebrophylline, Aminophylline, Theophylline*<br><b>Exception</b> Dyphylline</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Serum theophylline concentration (based on 300 mg twice daily) increased at least 48% in a patient within 6 weeks of initiating propafenone (150 mg 3 times/day).<sup>1</sup> Symptoms of toxicity were evident. Dechallenge and rechallenge with propafenone confirmed the interaction in this patient. Upon rechallenge, serum theophylline concentrations increased to unacceptable levels within one week. Another case report describes increased serum theophylline concentrations and a 25-69% reduction in theophylline clearance with concurrent propafenone (initiated at 150 mg 3 times/day and increased to 300 mg 3 times/day).<sup>2</sup> Theophylline was eventually discontinued, in part due to the increased serum concentrations.<br><br>The specific mechanism of this interaction is not certain, but it is suspected that propafenone inhibits the CYP1A2-mediated metabolism of theophylline. Both propafenone and theophylline are both CYP1A2 substrates, and propafenone was shown to be a moderately potent inhibitor of CYP1A2 in an in vitro study in human liver microsomes.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Lee BL and Dohrmann ML, “Theophylline Toxicity Ater Propafenone Treatment: Evidence for Drug Interaction,” <i>Clin Pharmacol Ther</i>, 1992, 51:353-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1544292\">[PubMed 1544292]</a></p>\n<p>2. Spinler SA, Gammaitoni A, Charland SL, et al, “Propafenone-Theophylline Interaction,” <i>Pharmacotherapy</i>, 1993, 13:68-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8437970\">[PubMed 8437970]</a></p>\n<p>3. Kobayashi K, Nakajima M, Chiba K, et al, “Inhibitory Effects of Antiarrhythmic Drugs on Phenacetin O-deethylation Catalysed by Human CYP1A2,” <i>Br J Clin Pharmacol</i>, 1998, 45(4):361-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9578183\">[PubMed 9578183]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3259":"<p><b>Title</b> Vitamin K Antagonists / Propafenone</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Propafenone may increase the serum concentration of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Onset</b> Delayed <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased anticoagulant effects (i.e., increased INR, signs/symptoms of bleeding) of the vitamin K antagonists if propafenone is initiated/dose increased, or decreased INR/effects if propafenone is discontinued/dose decreased.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Mean steady state serum warfarin concentrations (based on 5 mg/day) increased 39% in 8 healthy subjects when administered with propafenone (225 mg 3 times/day) for one week.<sup>1</sup> Increased clinical effects of warfarin (i.e., increased prothrombin times) have also been reported with concurrent propafenone in warfarin-treated patients.<sup>2</sup><br><br>The mechanism of this interaction is likely propafenone inhibition of warfarin metabolism. An in vitro study in human liver microsomes found that propafenone was a moderate inhibitor (capable of inhibiting up to 40% of the metabolism) of R-warfarin (approximately 5X less potent enantiomer vs. S-warfarin).<sup>3</sup> Similarly, propafenone was a moderate inhibitor of both R- and S-acenocoumarol (another vitamin K antagonist) in the same study. Propafenone has been shown to be a modest inhbitor of CYP1A2,<sup>4</sup> which is involved in R-warfarin metabolism, making this a likely explanation for these in vitro findings.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kates RE, Yee YG, and Kirsten EB, “Interaction Between Warfarin and Propafenone in Healthy Volunteers,” <i>Clin Pharmacol Ther</i>, 1987, 42:305-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3621785\">[PubMed 3621785]</a></p>\n<p>2. Prescribing information. Rhythmol (propafenone). Research Triangle Park, NC: GlaxoSmithKline, October 2009.</p>\n<p>3. Hermans JJ, Thijssen HH, “Human Liver Microsomal Metabolism of the Enantiomers of Warfarin and Acenocoumarol: P450 Isozyme Diversity Determines the Differences in their Pharmacokinetics,” <i>Br J Pharmacol</i>, 1993, 110(1):482-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8220911\">[PubMed 8220911]</a></p>\n<p>4. Kobayashi K, Nakajima M, Chiba K, et al, “Inhibitory Effects of Antiarrhythmic Drugs on Phenacetin O-deethylation Catalysed by Human CYP1A2,” <i>Br J Clin Pharmacol</i>, 1998, 45(4):361-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9578183\">[PubMed 9578183]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3261":"<p><b>Title</b> Vitamin K Antagonists / Antithyroid Agents</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antithyroid Agents may diminish the anticoagulant effect of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of vitamin K antagonists if an antithyroid agent is initiated/dose increased, or increased effects if an antithyroid agent is discontinued/dose decreased. Monitoring of thyroid function tests may be useful for anticipating necessary changes in anticoagulant dose.</p>\n<div>\n <p><b>Antithyroid Agents Interacting Members</b> Carbimazole, MethIMAzole, Potassium Iodate, Potassium Iodide, Propylthiouracil*</p>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The anticoagulant response to vitamin K derivatives (e.g., warfarin) may be increased in hyperthyroid patients, and decreased in hypothyroid patients, compared to euthyroid patients.<sup>1,2,3,4,5,6</sup> Hyperthyroid patients appear to metabolize vitamin K-dependent clotting factors faster than euthyroid patients, and thus vitamin K antagonists face less opposition to their effects. The opposite is true in hypothyroid patients. Consequently, when an antithyroid product is initiated/dose increased, the response to the vitamin K antagonist is antagonized; greater anticoagulant doses may be needed. In addition, propylthiouracil alone has been associated with hypoprothrombinemia.<sup>7,8,9</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Vagenakis AG, Cote R, Miller ME, et al, “Enhancement of Warfarin-Induced Hypoprothrombinemia by Thyrotoxicosis,” <i>Johns Hopkins Med J</i>, 1972, 131:69-73. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4114451\">[PubMed 4114451]</a></p>\n<p>2. Self T, Weisburst M, Wooten E, et al, “Warfarin-Induced Hypoprothrombinemia: Potentiation by Hyperthyroidism,” <i>JAMA</i>, 1975, 231:1165-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1172818\">[PubMed 1172818]</a></p>\n<p>3. Hansten PD, “Oral Anticoagulants and Drugs Which Alter Thyroid Function,” <i>Drug Intell Clin Pharm</i>, 1980, 14:331.</p>\n<p>4. Walters MB, “The Relationship Between Thyroid Function and Anticoagulant Therapy,” <i>Am J Cardiol</i>, 1963, 11:112. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=13998701\">[PubMed 13998701]</a></p>\n<p>5. Akin F, Yaylali GF, Bastemir M, et al, “Effect of Methimazole on Warfarin Anticoagulation in a Case of Graves' Disease,” <i>Blood Coagul Fibrinolysis</i>, 2008, 19(1):89-91. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18180622\">[PubMed 18180622]</a></p>\n<p>6. Busenbark LA, Cushnie SA, “Effect of Graves' Disease and Methimazole on Warfarin Anticoagulation,” <i>Ann Pharmacother</i>, 2006, 40(6):1200-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16735660\">[PubMed 16735660]</a></p>\n<p>7. Naeye RL, et al, “Hemorrhagic State After Therapy With Propylthiouracil,” <i>Am J Clin Path</i>, 1960, 34:254.</p>\n<p>8. Gotta AW, Sullivan CA, Seaman J, et al, “Prolonged Intraoperative Bleeding Caused by Propylthiouracil-Induced Hypoprothrombinemia,” <i>Anesthesiology</i>, 1972, 37:562-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5079309\">[PubMed 5079309]</a></p>\n<p>9. Greenstein RH, “Hypoprothrombinemia Due to Propylthiouracil Therapy,” <i>JAMA</i>, 1960, 173:1014. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=13851643\">[PubMed 13851643]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3262":"<p><b>Title</b> QuiNIDine / Rifamycin Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Rifamycin Derivatives may decrease the serum concentration of QuiNIDine. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Consider alternatives to combination treatment with quinidine and rifampin due to large potential decreases in quinidine concentrations. Monitor for decreased serum concentrations/therapeutic effects of quinidine if any rifamycin derivative is initiated/dose increased, or increased effects if a rifamycin derivative is discontinued/dose decreased. In order of potency/risk: rifampin &gt; rifapentine &gt; rifabutin.</p>\n<div>\n <p><b>Rifamycin Derivatives Interacting Members</b> Rifabutin, RifAMPin*, Rifapentine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The AUC of quinidine was decreased by 83% in healthy subjects when administered concomitantly with rifampin (600 mg/day).<sup>1,2</sup> The half-life of quinidine was decreased by approximately 60%. The apparent oral clearance of quinidine was 9-fold greater in subjects receiving rifampin in a clinical study of healthy volunteers.<sup>3</sup> Several case reports decreased quinidine concentration/loss of therapeutic effect with initiation of rifampin, and increased quinidine concentrations/effects with discontinuation of rifampin.<sup>4,5,6</sup> <br><br>The likely primary mechanism of this interaction is induction of CYP3A4 mediated quinidine metabolism by rifampin. 3-hydroxylation of quinidine (a marker of CYP3A4 activity) and elevated ratio of 3-hydroxyquinidine concentration to quinidine concentration have both been demonstrated in subjects receiving rifampin.<sup>3,7</sup> Rifabutin and rifapentine are also CYP3A4 inducers and may affect quinidine disposition in a similar manner, although clinical data confirming this effect are lacking.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Twum-Barima Y and Carruthers SG, “Evaluation of Rifampicin-Quinidine Interaction,” <i>Clin Pharmacol Ther</i>, 1980, 27:290.</p>\n<p>2. Twum-Barima Y and Carruthers SG, “Quinidine-Rifampicin Interaction,” <i>N Engl J Med</i>, 1981, 304:1466. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7231477\">[PubMed 7231477]</a></p>\n<p>3. Damkier P, Hansen LL and Brosen K, “Rifampicin Treatment Greatly Increases the Apparent Oral Clearance of Quinidine,” <i>Pharmacol Toxicol</i>, 1999, 85(6):257-62. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10628900\">[PubMed 10628900]</a></p>\n<p>4. Ahmad D, Mathur P, Ahunjma S, et al, “Rifampicin-Quinidine Interaction,” <i>Br J Dis Chest</i>, 1979, 73:409. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=554671\">[PubMed 554671]</a></p>\n<p>5. Schwartz A and Brown JR, “Quinidine-Rifampin Interaction,” <i>Am Heart J</i>, 1984, 107:789-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6702573\">[PubMed 6702573]</a></p>\n<p>6. Bussey HI, Merritt GJ, and Hill EG, “The Influence of Rifampin on Quinidine and Digoxin,” <i>Arch Intern Med</i>, 1984, 144:1021-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6712395\">[PubMed 6712395]</a></p>\n<p>7. Bidstrup TB, Stilling N, Damkier P, et al, “Rifampicin Seems to Act as Both an Inducer and an Inhibitor of the Metabolism of Repaglinide,” <i>Eur J Clin Pharmacol</i>, 2004, 60(2):109-14. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15034704\">[PubMed 15034704]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3263":"<p><b>Title</b> Neuromuscular-Blocking Agents / QuiNIDine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> QuiNIDine may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <b>Severity</b> Major <b>Onset</b> Immediate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased/revitalized therapeutic effects of neuromuscular blocking agents (NMBA) if quinidine is administered concomitant with, or within a few hours after, the administration of the NMBA.</p>\n<div>\n <p><b>Neuromuscular-Blocking Agents Interacting Members</b> Atracurium, Cisatracurium, Mivacurium, Pancuronium, Rocuronium, Succinylcholine*, Vecuronium</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Neuromuscular blockade and associated respiratory compromise developed in a postoperative patient, who had seemingly recovered from intraoperative dimethyltubocurarine administration, within 15 minutes of receiving quinidine (200 mg intravenously).<sup>1</sup> Respiratory distress lasted for more than 2 hours and was managed with intubation and respiratory support. Similar reports associated with succinylcholine and tubocurarine have been published.<sup>2,3,4</sup> <br><br>The mechanism of this interaction is not well understood. Quinidine may inhibit the synthesis of acetylcholine and thereby diminish transmission of action potentials.<sup>5</sup> Additionally, quinidine inhibition of plasma pseudocholinesterase may decrease metabolism of succinylcholine, thereby further potentiating its effects.<sup>6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Schmidt JL, Vick NA, and Sadove MS, “The Effect of Quinidine on the Action of Muscle Relaxants,” <i>JAMA</i>, 1963, 183:669. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=13992012\">[PubMed 13992012]</a></p>\n<p>2. Way WL, Katzung BG, and Larson CP, “Recurarization With Quinidine,” <i>JAMA</i>, 1967, 200:163. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6071389\">[PubMed 6071389]</a></p>\n<p>3. Grogono AW, “Anesthesia for Atrial Defibrillation. Effect of Quinidine on Muscular Relaxation,” <i>Lancet</i>, 1963, ii:1039. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14062727\">[PubMed 14062727]</a></p>\n<p>4. Kambam JR, Franks JJ, Naukam R, et al, “Effect of Quinidine on Plasma Cholinesterase Activity and Succinylcholine Neuromuscular Blockade,” <i>Anesthesiology</i>, 1987, 67:858-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3674502\">[PubMed 3674502]</a></p>\n<p>5. Kambam JR, Day P, Jansen VE, et al, “Quinidine Inhibits Choline Acetyltransferase Activity,” <i>Anesthesiology</i>, 1989, 71:A819.</p>\n<p>6. Kambam JR, Franks JJ and Smith BE, “Inhibitory Effect of Quinidine on Plasma Pseudocholinesterase Activity in Pregnant Women,” <i>Am J Obstet Gynecol</i>, 1987, 157(4 Pt 1):897-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3674164\">[PubMed 3674164]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3264":"<p><b>Title</b> Vitamin K Antagonists / QuiNIDine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> QuiNIDine may enhance the anticoagulant effect of Vitamin K Antagonists. Note that the INR/PT might be unchanged in the face of increased bleeding. <b>Severity</b> Moderate <b>Onset</b> Delayed <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased INR/prothrombin time (PT) or signs/symptoms of bleeding if quinidine is initiated/dose increased, or decreased INR/PT if quinidine is discontinued/dose decreased. Note that the INR/PT might be unchanged in the face of increased bleeding.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Case reports describe bleeding episodes in warfarin-stable patients within a few days of initiating quinidine therapy.<sup>1,2,3</sup> In contrast, the prothrombin times of 10 warfarin-treated patients were unaffected by two weeks of concomitant quinidine therapy (800 mg/day).<sup>4</sup> The mechanism of these effects is unknown. The risk factors that might lead to effects in some patients, while not in others, is likewise unknown.<br><br>Studies in human liver microsomes and human hepatocyte suspensions both found that the 4'-hydroxylation of S-warfarin and the 10-hydroxylation of R-warfarin were increased 3- to 5-fold with concurrent quinidine.<sup>5</sup> Data from liver microsomes in different species of animals have similarly found an increase in R-warfarin 10-hydroxylation with quinidine, though there were considerable inter-species differences in the findings.<sup>6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Gazzaniga AB and Stewart DR, “Possible Quinidine-Induced Haemorrhage in a Patient on Warfarin Sodium,” <i>N Engl J Med</i>, 1969, 280:711. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5766081\">[PubMed 5766081]</a></p>\n<p>2. Koch-Weser J, “Quinidine-Induced Hypoprothrombinemic Haemorrhage in Patients on Chronic Warfarin Therapy,” <i>Ann Intern Med</i>, 1968, 68:511. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5643674\">[PubMed 5643674]</a></p>\n<p>3. Jones FL Jr, “More on Quinidine-Induced Hypoprothrombinaemia,” <i>Ann Intern Med</i>, 1986, 69:1074. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5698476\">[PubMed 5698476]</a></p>\n<p>4. Udall J, “Drug Interference With Warfarin Therapy,” <i>Clin Med</i>, 1970, 77:20.</p>\n<p>5. Ngui JS, Chen Q, Shou M, et al, “In Vitro Stimulation of Warfarin Metabolism by Quinidine: Increases in the Formation of 4'- and 10-Hydroxywarfarin,” <i>Drug Metab Dispos</i>, 2001, 29(6):877-86. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11353757\">[PubMed 11353757]</a></p>\n<p>6. Chen Q, Tan E, Strauss JR, et al, “Effect of Quinidine on the 10-Hydroxylation of R-Warfarin: Species Differences and Clearance Projection,” <i>J Pharmacol Exp Ther</i>, 2004, 311(1):307-14. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15163679\">[PubMed 15163679]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3265":"<p><b>Title</b> HMG-CoA Reductase Inhibitors (Statins) / Rifamycin Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Rifamycin Derivatives may decrease the serum concentration of HMG-CoA Reductase Inhibitors (Statins). <b>Severity</b> Major <b>Onset</b> Delayed <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> With several HMG-CoA reductase inhibitors, there appears to be a risk for suboptimal treatment response with concomitant use of rifamycin derivatives. Consider using a noninteracting antilipemic agent with chronic rifamycin therapy when possible (note: pitavastatin concentrations may increase rather than decrease during concomitant use of rifamycin derivatives). Monitor for altered therapeutic effects of HMG-CoA reductase inhibitors if a rifamycin derivative is used. Short-term rifamycin therapy may be of less clinical concern. Rifabutin and fluvastatin, or possibly pravastatin, would appear to be lower risk combinations.</p>\n<div>\n <p><b>HMG-CoA Reductase Inhibitors (Statins) Interacting Members</b> AtorvaSTATin*, Fluvastatin, Lovastatin, Pravastatin, Red Yeast Rice, Simvastatin*<br><b>Exceptions</b> Pitavastatin, Rosuvastatin</p>\n <p><b>Rifamycin Derivatives Interacting Members</b> Rifabutin, RifAMPin*, Rifapentine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The AUC and maximum serum concentration (Cmax) of simvastatin (40 mg single dose) were decreased by 87% and 90%, respectively, in 10 healthy volunteers when administered following a 5-day course of rifampin (600 mg/day).<sup>1</sup> Similar reductions in the metabolite, simvastatin acid, were noted. The half-life of neither simvastatin nor simvastatin acid were altered. The AUC of atorvastatin (40 mg) was decreased 80% in 10 healthy volunteers when administered following a 5-day course of rifampin (600 mg daily).<sup>2</sup> The mechanism of this interaction is likely due to CYP3A4 and/or p-glycoprotein induction by rifampin leading to increased atorvastatin and simvastatin metabolism/excretion. Rifabutin may affect these drugs in a similar fashion. Other CYP3A4-metabolized HMG-CoA reductase inhibitors (e.g., lovastatin) may be similarly affected by rifamycins. <br><br>Rifampin also induces CYP2C9, and will likely increase the metabolism of fluvastatin. Pravastatin is not significantly metabolized via CYP isoenzymes, but may be affected by rifampin via p-glycoprotein induction. Rosuvastatin does not appear to be affected by either CYP3A4 or p-glycoprotein.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Kyrklund C, Backman JT, Kivisto KT, et al, “Rifampin Greatly Reduces Plasma Simvastatin and Simvastatin Acid Concentrations,” <i>Clin Pharmacol Ther</i>, 2000, 68(6):592-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11180018\">[PubMed 11180018]</a></p>\n<p>2. Backman JT, Luurila H, Neuvonen M, et al, “Rifampin Markedly Decreases and Gemfibrozil Increases the Plasma Concentrations of Atorvastatin and Its Metabolites,” <i>Clin Pharmacol Ther</i>, 2005, 78(2):154-67. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16084850\">[PubMed 16084850]</a></p>\n<p>3. Cooper KJ, Martin PD, Dane AL, et al, “Lack of Effect of Ketoconazole on the Pharmacokinetics of Rosuvastatin in Healthy Subjects,” <i>Br J Clin Pharmacol</i>, 2003, 55(1):94-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12534645\">[PubMed 12534645]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3267":"<p><b>Title</b> Tamoxifen / Rifamycin Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Rifamycin Derivatives may increase the metabolism of Tamoxifen. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Consider alternatives to combined therapy with rifampin and tamoxifen. If the combination cannot be avoided, monitor for reduced therapeutic effects of tamoxifen. It is not clear whether rifapentine or rifabutin would participate in this interaction. In order of CYP3A induction potency: rifampin &gt; rifapentine &gt; rifabutin.</p>\n<div>\n <p><b>Rifamycin Derivatives Interacting Members</b> Rifabutin, RifAMPin*, Rifapentine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> In a study of 10 healthy volunteers, the AUC of tamoxifen (80 mg single dose) and its N-desmethyl metabolite were decreased by 86% and 62%, respectively, following a 5-day course of rifampin (600 mg/day).<sup>1</sup> <br><br>The mechanism and clinical impact of this interaction have not been investigated. Rifampin induction of CYP3A mediated tamoxifen metabolism likely increases both tamoxifen clearance and the conversion of N-desmethyl tamoxifen to inactive metabolites. Since the therapeutic effects of tamoxifen appear to be dependent on formation of the major pharmacologically active metabolite endoxifen, a process catalyzed by CYP2D6,<sup>2</sup> the pharmacokinetic changes seen may therefore result in reduced tamoxifen efficacy.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kivisto KT, Billikka K, Nyman L, et al, “Tamoxifen and Toremifene Concentrations in Plasma Are Greatly Decreased by Rifampin,” <i>Clin Pharmacol Ther</i>, 1998, 64:648-54. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9871429\">[PubMed 9871429]</a></p>\n<p>2. Brauch H, Murdter TE, Eichelbaum M, et al, “Pharmacogenomics of Tamoxifen Therapy,” <i>Clin Chem</i>, 2009, 55(10):1770-82. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19574470\">[PubMed 19574470]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3269":"<p><b>Title</b> Vitamin K Antagonists / Rifamycin Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Rifamycin Derivatives may increase the metabolism of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for decreased prothrombin times (PT)/therapeutic effects of coumarin derivatives if a rifamycin derivative is initiated/dose increased, or increased PT/toxic effects if a rifamycin derivative is discontinued/dose decreased. In order of potency/risk: rifampin &gt; rifapentine &gt; rifabutin.</p>\n<div>\n <p><b>Rifamycin Derivatives Interacting Members</b> Rifabutin, RifAMPin*, Rifapentine</p>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The clearance of warfarin is significantly increased during concomitant therapy with rifampin.<sup>1,2,3,4,5,6</sup> Commensurate decreases in hypoprothrombinemic effects occur. The serum warfarin concentration (1.5 mg/kg single oral dose) was decreased 57% in 10 normal subjects when administered following a 3-day course of rifampin (600 mg/day).<sup>2</sup> A 21-day concomitant therapy study demonstrated an 85% decrease in serum warfarin concentrations.<sup>4</sup> Case reports demonstrate the need for twice as much warfarin during concomitant rifampin therapy in order to maintain adequate anticoagulation.<sup>1,3</sup> Maximum effects of rifampin occur with 5-7 days of initiating rifampin in a warfarin-stable patient. A similar period of time is required following discontinuation of rifampin for warfarin effects to return to prerifampin levels. The mechanism of this interaction is related to the ability of rifampin to induce CYP isoenzymes, and thus increase warfarin metabolism.<sup>7</sup> Rifabutin and rifapentine will likely affect warfarin in a similar fashion, but to a lesser extent.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Romankiewicz JA and Ehrman M, “Rifampin and Warfarin: A Drug Interaction,” <i>Ann Intern Med</i>, 1975, 82(2):224-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1115445\">[PubMed 1115445]</a></p>\n<p>2. O’Reilly RA, “Interaction of Sodium Warfarin and Rifampin. Studies in Man,” <i>Ann Intern Med</i>, 1974, 81(3):337-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4852505\">[PubMed 4852505]</a></p>\n<p>3. Self TH and Mann RB, “Interaction of Rifampin and Warfarin,” <i>Chest</i>, 1975, 67(4):490-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1122784\">[PubMed 1122784]</a></p>\n<p>4. O’Reilly RA, “Interaction of Chronic Daily Warfarin Therapy and Rifampin,” <i>Ann Intern Med</i>, 1975, 83(4):506-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1166982\">[PubMed 1166982]</a></p>\n<p>5. Almog S, Martinowitz U, Halkin H, et al, “Complex Interaction of Rifampin and Warfarin,” <i>South Med J</i>, 1988, 81(10):1304-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3175736\">[PubMed 3175736]</a></p>\n<p>6. Casner PR, “Inability to Attain Oral Anticoagulation: Warfarin-Rifampin Interaction Revisited,” <i>South Med J</i>, 1996, 89(12):1200-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8969357\">[PubMed 8969357]</a></p>\n<p>7. Boekhout-Mussert RJ, Bieger R, van Brummelen A, et al, “Inhibition by Rifampicin of the Anticoagulant Effect of Phenprocoumon,” <i>JAMA</i>, 1974, 229(14):1903-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4479144\">[PubMed 4479144]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3272":"<p><b>Title</b> Zidovudine / Rifamycin Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Rifamycin Derivatives may decrease the serum concentration of Zidovudine. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased serum concentrations/therapeutic effects of zidovudine if rifampin is initiated/dose increased, or increased serum concentrations/effects if rifampin is discontinued/dose decreased. In order of potency/risk: rifampin &gt; rifapentine &gt; rifabutin. Consider risks associated with reduced efficacy of retroviral therapy relative to anticipated duration of rifampin treatment.</p>\n<div>\n <p><b>Rifamycin Derivatives Interacting Members</b> RifAMPin*, Rifapentine<br><b>Exception</b> Rifabutin</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Zidovudine (200 mg every 8 hours) AUC and maximum plasma concentration (Cmax) were an average of 47% abd 43% lower, respectively, with concurrent rifampin (600 mg/day x 14 days) in a study of 8 HIV-infected volunteers.<sup>1</sup> Similarly, a comparison of zidovudine concentrations in 4 rifampin-treated patients to those of 69 controls found substantially lower zidovudine concentrations among those patients receiving rifampin (zidovudine AUC approximately 60% lower with rifampin).<sup>2</sup> Though the magnitude of this apparent interaction may be of clinical relevance, zidovudine prescribing information offers no specific recommendation regarding how best to manage this interaction.<sup>3</sup><br><br>The other rifamycins rifapentine and rifabutin would be expected to have less substantial interactions with zidovudine since they are considered less powerful inducers of drug metabolizing enzymes and drug transporters than rifampin. Though data with rifapentine are not available, one study with rifabutin (300 mg/day) concluded that zidovudine concentrations were only minimally altered (less than 25%) by rifabutin (n=9).<sup>4</sup><br><br>Of note, one study evaluating the impact of zidovudine on rifabutin pharmacokinetics also concluded that zidovudine did not significantly interact with rifabutin.<sup>5</sup><br><br>The mechanism by which rifampin (and to a lesser degree, the other rifamycin derivatives) interacts with zidovudine is likely induction of zidovudine metabolism (via glucuronidation and amination).<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Gallicano KD, Sahai J, Shukla VK, et al, “Induction of Zidovudine Glucuronidation and Amination Pathways by Rifampicin in HIV-Infected Patients,” <i>Br J Clin Pharmacol</i>, 1999, 48(2):168-79. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10417493\">[PubMed 10417493]</a></p>\n<p>2. Burger DM, Meenhorst PL, Koks CH, et al, “Pharmacokinetic Interaction Between Rifampin and Zidovudine,” <i>Antimicrob Agents Chemother</i>, 1993, 37(7):1426-31. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8363370\">[PubMed 8363370]</a></p>\n<p>3. Prescribing information. Retrovir (zidovudine). Research Triangle Park, NC: GlaxoSmithKline, May 2010.</p>\n<p>4. Gallicano K, Sahai J, Swick L, et al, “Effect of Rifabutin on the Pharmacokinetics of Zidovudine in Patients Infected with Human Immunodeficiency Virus,” <i>Clin Infect Dis</i>, 1995, 21(4):1008-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8645788\">[PubMed 8645788]</a></p>\n<p>5. Li RC, Nightingale S, Lewis RC, et al, “Lack of Effect of Concomitant Zidovudine on Rifabutin Kinetics in Patients with AIDS-Related Complex,” <i>Antimicrob Agents Chemother</i>, 1996, 40(6):1397-402. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8726008\">[PubMed 8726008]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3275":"<p><b>Title</b> Theophylline Derivatives / Protease Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Protease Inhibitors may decrease the serum concentration of Theophylline Derivatives. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased serum concentrations/therapeutic effects of theophylline if a protease inhibitor is initiated/dose increased, or increased serum concentrations/toxic effects if a protease inhibitor is discontinued/dose decreased.</p>\n<div>\n <p><b>Protease Inhibitors Interacting Members</b> Atazanavir, Darunavir, Indinavir, Lopinavir, Nelfinavir, Ritonavir*, Saquinavir, Tipranavir<br><b>Exception</b> Fosamprenavir</p>\n <p><b>Theophylline Derivatives Interacting Members</b> Acebrophylline, Aminophylline, Theophylline*<br><b>Exception</b> Dyphylline</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The AUC of theophylline (3 mg/kg every 8 hours) was reduced by 43% in 13 subjects following 10 days of concomitant therapy with ritonavir (500 mg every 12 hours).<sup>1</sup> This change was evident when compared with 11 subjects who received no ritonavir. The theophylline C<sub>max</sub> of the ritonavir-treated group was decreased 32%. The mechanism of this interaction is unclear. The potential for the protease inhibitors to induce CYP1A2 isoenzymes (the primary metabolic pathway for theophylline), or to affect a different metabolic pathway, is unclear. The effect of other protease inhibitors is therefore difficult to predict.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Norvir [package insert]. North Chicago, IL: Abbott Laboratories, 2000.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3276":"<p><b>Title</b> Vitamin K Antagonists / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> St John's Wort may increase the metabolism of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Consider avoiding the use of St John's wort in patients being treated with warfarin. Monitor for decreased prothrombin time (PT)/therapeutic effects of coumarin derivatives if St John's wort is initiated/dose increased, or increased PT/effects if St John's wort is discontinued/dose decreased.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Information on 7 cases (reported to the Swedish Medical Products Agency) have been published describing diminished hypoprothrombinemic response to warfarin in patients receiving St John's Wort.<sup>1,2</sup> Dechallenge in 4 of the cases resulted in increased warfarin effects. The AUC of warfarin (25 mg single dose) was decreased 20% in 12 normal subjects when administered following a 14-day course of St John's wort.<sup>3</sup> Hypericin, an active component of St John's Wort, has been implicated as a CYP isoenzyme inducer, and may be the cause of the problems observed in these cases.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Yue QY, Bergquist C, and Gerden B, “Safety of St John’s Wort (Hypericum Perforatum),” <i>Lancet</i>, 2000, 355(9203):576-77, (letter). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10683030\">[PubMed 10683030]</a></p>\n<p>2. De Smet PA and Touw DJ, “Safety of St John’s Wort,” <i>Lancet</i>, 2000, 355(9203):575-76 (letter). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10683028\">[PubMed 10683028]</a></p>\n<p>3. Jiang X, Williams KM, Liauw WS, et al, “Effect of St John's Wort and Ginseng on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Subjects,” <i>Br J Clin Pharmacol</i>, 2004, 57(5):592-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15089812\">[PubMed 15089812]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3277":"<p><b>Title</b> Vitamin K Antagonists / Sucralfate</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Sucralfate may diminish the anticoagulant effect of Vitamin K Antagonists. Sucralfate may decrease the serum concentration of Vitamin K Antagonists. Specifically, sucralfate may decrease the absorption of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Administer vitamin K antagonists at least 2 hours before or at least 6 hours after sucralfate. Concomitant administration should be avoided. Monitor for decreased INR/prothrombin time (PT)/therapeutic effects if sucralfate is initiated/dose increased, or increased INR/PT/effects if sucralfate is discontinued/dose decreased.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Neither pharmacokinetic nor pharmacodynamic changes were noted to occur in 8 elderly warfarin-treated patients following 2 weeks of concomitant therapy with sucralfate (1 g 3 times/day).<sup>1</sup> Results were similar in another study.<sup>2</sup> In contrast, at least 4 case reports describe significantly reduced warfarin effects in elderly patients receiving concomitant sucralfate.<sup>3,4,5,6</sup> Two of the reports describe the return of warfarin responses to normal following discontinuation of the sucralfate.<sup>3,5</sup> <br><br>The mechanism behind this interaction most likely involves sucralfate binding to warfarin within the gastrointestinal tract and thereby reducing warfarin absorption. Sucralfate prescribing information states potential drug-drug interactions associated with its use, may be avoided by administering concomitant drugs 2 hours prior to sucralfate.<sup>7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Neuvonen PJ, Jaakkola A, Totterman J, et al, “Clinically Significant Sucralfate-Warfarin Interaction is Not Likely,” <i>Br J Clin Pharmacol</i>, 1985, 20:178-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3840028\">[PubMed 3840028]</a></p>\n<p>2. Talbert RL, Dalmady-Israel C, Bussey HI, et al, “Effect of Sucralfate on Plasma Warfarin Concentration in Patients Requiring Chronic Warfarin Therapy,” <i>Drug Intell Clin Pharm</i>, 1985, 19:456.</p>\n<p>3. Mungall D, Talbert RL, Phillips C, et al, “Sulcrate and Warfarin,” <i>Ann Intern Med</i>, 1983, 98:557. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6687662\">[PubMed 6687662]</a></p>\n<p>4. Braverman SE and Marino MT, “Sucralfate-Warfarin Interaction,” <i>Drug Intell Clin Pharm</i>, 1988, 22:913. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3234259\">[PubMed 3234259]</a></p>\n<p>5. Rey AM and Gums JG, “Altered Absorption of Digoxin, Sustained-Release Quinidine, and Warfarin With Sucralfate Absorption,” <i>DICP</i>, 1991, 25:745-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1949932\">[PubMed 1949932]</a></p>\n<p>6. Parrish RH, Waller B, and Gondalia BG, “Sucralfate-Warfarin Interaction,”<i>Ann Pharmacother</i>, 1992, 26:1015-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1504385\">[PubMed 1504385]</a></p>\n<p>7. Prescribing information. Carafate (sucralfate). Birmingham, AL: Axcan Scandipharm Inc., April 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3278":"<p><b>Title</b> Vitamin K Antagonists / Sulfinpyrazone</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Sulfinpyrazone may decrease the metabolism of Vitamin K Antagonists. Sulfinpyrazone may decrease the protein binding of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Onset</b> Rapid <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased prothrombin time (PT)/toxic effects of coumarin derivatives if sulfinpyrazone is initiated/dose increased, or decreased PT/effects if sulfinpyrazone is discontinued/dose decreased.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Increased prothrombin time (PT) and associated bleeding (severe at times) have been reported in a number of cases where warfarin-treated patients have started sulfinpyrazone therapy.<sup>1,2,3,4,5,6,7,8,9</sup> The effects can occur quickly (within less than 3 days). Two potential mechanism for this interaction have been proposed: Sulfinpyrazone displacement of warfarin from plasma protein binding sites<sup>10</sup>, and inhibition of CYP2C9 with a resultant decrease in warfarin metabolism<sup>1,11</sup> Compelling arguments have been published that refute the protein-binding mechanism as being plausible.<sup>12,13,14,15</sup> Dicumarol is also a CYP2C9 substrate.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Miners JO, Foenander T, Wanwimolruk S, et al, “Interaction of Sulphinpyrazone With Warfarin,” <i>Eur J Clin Pharmacol</i>, 1982, 22:327-31. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7106169\">[PubMed 7106169]</a></p>\n<p>2. Weiss M, “Potentiation of Coumarin Effect by Sulphinpyrazone,” <i>Lancet</i>, 1979, i:609. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=85191\">[PubMed 85191]</a></p>\n<p>3. Davis JW and Johns LE, “Possible Interaction of Sulphinpyrazone With Coumarins,” <i>N Engl J Med</i>, 1978, 299:955. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=692605\">[PubMed 692605]</a></p>\n<p>4. Bailey RR and Reddy J, “Potentiation of Warfarin Action by Sulphinpyrazone,” <i>Lancet</i>, 1980, i:254. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6101699\">[PubMed 6101699]</a></p>\n<p>5. Nenci GG, Agnelli G, and Berretini M, “Biphasic Sulphinpyrazone-Warfarin Interaction,” <i>Br Med J</i>, 1981, 282:1361. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6786498\">[PubMed 6786498]</a></p>\n<p>6. Gallus A and Birkett D, “Sulphinpyrazone and Warfarin: A Probable Interaction,” <i>Lancet</i>, 1980, i:535. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6102248\">[PubMed 6102248]</a></p>\n<p>7. Jamil A, Reid JM, and Messer M, “Interaction between Sulphinpyrazone and Warfarin,” <i>Chest</i>, 1981, 79:375.</p>\n<p>8. Girolami A, Schivazappa L, Fabris F, et al, “Biphasic Sulphinpyrazone-Warfarin Interaction,” <i>Br Med J</i>, 1981, 283:1338.</p>\n<p>9. Mattingly D, Bradley M, and Selley PJ, “Hazards of Sulphinpyrazone,” <i>Br Med J</i>, 1978, 2:1786. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=310703\">[PubMed 310703]</a></p>\n<p>10. Tulloch JA and Marr TC, “Sulphinpyrazone and Warfarin After Myocardial Infarction,” <i>Br Med J</i>, 1979, ii:133. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=466316\">[PubMed 466316]</a></p>\n<p>11. Toon S, Low LK, Gibaldi M, et al, “The Warfarin-Sulfinpyrazone Interaction: Stereochemical Considerations,” <i>Clin Pharmacol Ther</i>, 1986, 39:15-24. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3943265\">[PubMed 3943265]</a></p>\n<p>12. Benet LZ and Hoener B, “Changes in Plasma Protein Binding Have Little Clinical Relevance,” <i>Clin Pharmacol Ther</i>, 2002, 71(3):115-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11907485\">[PubMed 11907485]</a></p>\n<p>13. MacKicham JJ, “Protein Binding Drug Displacement Interactions Fact or Fiction?” <i>Clin Pharmacokinet</i>, 1989, 16:65-73. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2656044\">[PubMed 2656044]</a></p>\n<p>14. Rolan PE, “Plasma Protein Binding Displacement Interactions - Why Are They Still Regarded as Clinically Important?” <i>Br J Clin Pharmacol</i>, 1994, 37:125-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8186058\">[PubMed 8186058]</a></p>\n<p>15. Sansom LN, Evans AM, “What is the True Clinical Significance of Plasma Protein Binding Displacement Interactions?” <i>Drug Saf</i>, 1995, 12(4):227-33. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7646820\">[PubMed 7646820]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3279":"<p><b>Title</b> Tetracyclines / Zinc Salts</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (oral): Only oral preparations of zinc salts and tetracycline antibiotics are expected to participate in this interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Zinc Salts may decrease the absorption of Tetracyclines. Only a concern when both products are administered orally. <b>Severity</b> Moderate <b>Onset</b> Immediate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Consider doxycycline as a noninteracting tetracycline derivative. Separate dose administration of oral tetracycline derivative and oral zinc salts by at least 2 hours to minimize interaction. Monitor for reduced therapeutic effect of tetracycline derivative is coadministered with an oral zinc salt (whether alone in as part of a multiple vitamin/mineral supplement).</p>\n<div>\n <p><b>Tetracyclines Interacting Members</b> Demeclocycline, Lymecycline, Minocycline, Oxytetracycline, Tetracycline (Systemic)*<br><b>Exception</b> Doxycycline</p>\n <p><b>Zinc Salts Interacting Members</b> Polaprezinc, Zinc Acetate, Zinc Gluconate, Zinc Sulfate*<br><b>Exception</b> Zinc Chloride</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The AUC of tetracycline (500 mg single oral dose) was decreased by approximately 40% in 7 healthy subjects when coadministered with zinc sulfate (200 mg single oral dose containing 45 mg elemental zinc).<sup>1</sup> This finding has been confirmed by others.<sup>2</sup> Tetracycline and zinc appear to form a relatively insoluble chelate when mixed in the GI tract, and thus tetracycline absorption is diminished. The absorption of zinc may also be diminished by this interaction.<sup>3</sup> Doxycycline does not appear to be significantly affected by zinc.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Penttila O, Hurme H, Neuvonen PJ. Effect of zinc sulphate on the absorption of tetracycline and doxycycline in man. <i>Eur J Clin Pharmacol</i>. 1975;9(2-3):131-134. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=786686\">[PubMed 786686]</a></p>\n<p>2. Mapp RK, McCarthy TJ. The effect of zinc sulphate and of bicitropeptide on tetracycline absorption. <i>S Afr Med J</i>. 1976;50(45):1829-1830. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=996681\">[PubMed 996681]</a></p>\n<p>3. Brion M, Lambs L, Berthon G. Metal ion-tetracycline interactions in biological fluids. Part 5. Formation of zinc complexes with tetracycline and some of its derivatives and assessment of their biological significance. <i>Agents Actions</i>. 1985;17(2):229-242. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4096307\">[PubMed 4096307]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3280":"<p><b>Title</b> Theophylline Derivatives / Thiabendazole</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Thiabendazole may decrease the metabolism of Theophylline Derivatives. <b>Severity</b> Moderate <b>Onset</b> Rapid <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> A reduction is the dosage of the theophylline derivative (possibly 50%) should be considered at the time of initiating thiabendazole. Monitor for increased serum concentrations/toxic effects of theophylline derivative if thiabendazole is initiated/dose increased, or decreased serum concentrations/effects if thiabendazole is discontinued/dose decreased. Mebendazole does not appear to interact with theophylline.</p>\n<div>\n <p><b>Theophylline Derivatives Interacting Members</b> Acebrophylline, Aminophylline*, Theophylline*<br><b>Exception</b> Dyphylline</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The clearance of aminophylline (6 mg/kg single IV dose) was decreased by 65% in 6 normal subjects when administered following a 3-day course of thiabendazole (1.5 g every 12 hours).<sup>1</sup> The theophylline half-life more than doubled. Several cases of elevated serum theophylline concentrations (some more than 100%), and associated toxicity, due to this interaction have been reported.<sup>2,3,4</sup> The mechanism of this interaction is unknown. It appears as though thiabendazole inhibits the metabolism of theophylline. Mebendazole does not appear to interact with theophylline.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Schneider D, Gannon R, Sweeney K, et al, “Theophylline and Antiparasitic Drug Interactions. A Case Report and a Study of the Influence of Thiabendazole and Mebendazole on Theophylline Kinetics in Adults,” <i>Chest</i>, 1990, 97:84-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2295264\">[PubMed 2295264]</a></p>\n<p>2. Sugar AM, Kearns PJ, Haulk AA, et al, “Possible Thiabendazole-Induced Theophylline Toxicity?” <i>Am Rev Resp Dis</i>, 1980, 122:501. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7416626\">[PubMed 7416626]</a></p>\n<p>3. Lew G, Murray WE, Lane JR, et al, “Theophylline-Thiabendazole Drug Interaction,” <i>Clin Pharm</i>, 1989, i:225-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2706897\">[PubMed 2706897]</a></p>\n<p>4. German T and Berger R, “Interaction of Theophylline and Thiabendazole in Patients With Chronic Obstructive Lung Disease,” <i>Am Rev Resp Dis</i>, 1992, 145:A807.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3281":"<p><b>Title</b> Theophylline Derivatives / Thyroid Products</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Thyroid Products may increase the metabolism of Theophylline Derivatives. <b>Severity</b> Moderate <b>Onset</b> Rapid <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased serum concentrations/therapeutic effects of theophylline derivatives if a thyroid product is initiated/dose increased, or increased serum concentrations/effects if a thyroid product is discontinued/dose decreased.</p>\n<div>\n <p><b>Theophylline Derivatives Interacting Members</b> Acebrophylline, Aminophylline, Theophylline*<br><b>Exception</b> Dyphylline</p>\n <p><b>Thyroid Products Interacting Members</b> Levothyroxine*, Liothyronine, Liotrix, Thyroid, Desiccated</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> There have been multiple case reports of the effect of altered thyroid status on theophylline clearance. Two case reports describe the resolution of theophylline toxicity with life-threatening manifestations in hypothyroid patients following approximately 2 months of thyroid hormone replacement therapy and normalization of thyroid status.<sup>1,2</sup> A third case report describes a 73% decrease in theophylline clearance with resolution of a hyperthyroid state.<sup>3</sup> In an observational study of 15 subjects with COPD and hyperthyroid, hypothyroid or euthyroid, the clearance of theophylline was 2.5-fold higher in hyperthyroid patient than in hypothyroid patients.<sup>4</sup> Although there was no significant difference in AUC, there was a large inter-individual variability in each of the groups analyzed. The mechanism of this interaction is likely the increase in metabolic clearance due to an increase in thyroid hormones.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Johnson CE and Cohen IA, “Theophylline Toxicity After Iodine 131 Treatment for Hyperthyroidism,” <i>Clin Pharm</i>, 1988, 7:620-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3168415\">[PubMed 3168415]</a></p>\n<p>2. Aderka D, Shavit G, Garfinkel D, et al, “Life-Threatening Theophylline Intoxication in a Hypothyroidic Patient,” <i>Respiration</i>, 1983, 44:77-80. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6828808\">[PubMed 6828808]</a></p>\n<p>3. Bauman JH, Teichman S, Wible DA, “Increased Theophylline Clearance in a Patient with Hyperthyroidism,” <i>Ann Allergy</i>, 1984, 52(2):94-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6696299\">[PubMed 6696299]</a></p>\n<p>4. Pokrajac M, Simic D, and Varagic VM, “Pharmacokinetics of Theophylline in Hyperthyroid and Hypothyroid Patients With Chronic Obstructive Pulmonary Disease,” <i>Eur J Clin Pharmacol</i>, 1987, 33:483-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3428340\">[PubMed 3428340]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3282":"<p><b>Title</b> Theophylline Derivatives / Ticlopidine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ticlopidine may increase the serum concentration of Theophylline Derivatives. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased serum concentrations/toxic effects of theophylline derivatives if ticlopidine is initiated/dose increased, or decreased serum concentrations/effects if ticlopidine is discontinued/dose decreased.</p>\n<div>\n <p><b>Theophylline Derivatives Interacting Members</b> Acebrophylline, Aminophylline, Theophylline*<br><b>Exception</b> Dyphylline</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The clearance of theophylline (5 mg/kg single oral dose) was reduced by an average of 37% with concurrent ticlopidine in a study of 10 healthy volunteers who received ticlopidine 250 mg twice daily for 10 days.<sup>1</sup> The likely mechanism for this interaction is ticlopidine inhibition of the CYP1A2 metabolism of theophylline.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Colli A, Buccino G, Cocciolo M, Parravicini R, Elli GM, Scaltrini G. Ticlopidine-theophylline interaction. <i>Clin Pharmacol Ther</i>. 1987;41(3):358-362. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3816023\">[PubMed 3816023]</a></p>\n<p>2. Kot M, Daniel WA. Effect of diethyldithiocarbamate (DDC) and ticlopidine on CYP1A2 activity and caffeine metabolism: an in vitro comparative study with human cDNA-expressed CYP1A2 and liver microsomes. <i>Pharmacol Rep</i>. 2009;61(6):1216-1220. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20081260\">[PubMed 20081260]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3283":"<p><b>Title</b> Zafirlukast / Theophylline Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Theophylline Derivatives may decrease the serum concentration of Zafirlukast. Zafirlukast may increase the serum concentration of Theophylline Derivatives. <b>Severity</b> Moderate <b>Onset</b> Rapid <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of zafirlukast if a theophylline derivative is initiated/dose increased, or increased toxicity if a theophylline derivative is discontinued/dose decreased. Rare increases in theophylline concentrations and effects have been noted during zafirlukast coadministration, but specific monitoring recommendations are lacking.</p>\n<div>\n <p><b>Theophylline Derivatives Interacting Members</b> Acebrophylline, Aminophylline, Theophylline*<br><b>Exception</b> Dyphylline</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> In a clinical study described in zafirlukast prescribing information, mean serum concentrations of zafirlukast (80 mg/day) were decreased by 30% in 13 asthmatic adult patients following the administration of theophylline (6 mg/kg single oral dose).<sup>1</sup> There was no observed effect of zafirlukast on theophylline concentrations. A second study of healthy children showed no significant changes in the pharmacokinetic properties of theophylline (16 mg/kg sustained release single oral dose) when coadministered with zafirlukast (20 mg orally daily).<br><br>One case report describes a 15 year old girl who experienced nausea and apparent increases in serum concentrations of theophylline (300 mg extended release orally twice daily) following initiation of zafirlukast (regimen not specified).<sup>2</sup> Theophylline was reinitiated (75 mg extended release orally twice daily), and addition of zafirlukast (20 mg twice daily) increased theophylline AUC by roughly 7 fold.<br><br>The mechanisms of these interactions are unknown. Based on in vitro data, zafirlukast could inhibit a number of enzymes involved in theophylline clearance (e.g. CYP3A, 1A2), but no significant inhibition would not be predicted at zafirlukast concentrations achieved clinically.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Katial RK, Stelzle RC, Bonner MW, et al, “A Drug Interaction Between Zafirlukast and Theophylline,” <i>Arch Intern Med</i>, 1998, 158(15):1713-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9701106\">[PubMed 9701106]</a></p>\n<p>2. Prescribing information. Accolate (zafirlukast). Wilmington, DE: AstraZeneca Pharmaceuticals LP, July 2010.</p>\n<p>3. Shader RI, Granda BW, von Moltke LL, et al, “Inhibition of Human Cytochrome P450 Isoforms in Vitro by Zafirlukast,” <i>Biopharm Drug Dispos</i>, 1999, 20(8):385-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10870095\">[PubMed 10870095]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3285":"<p><b>Title</b> Vitamin K Antagonists / Sulfonamide Antibiotics</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Sulfonamide Antibiotics may enhance the anticoagulant effect of Vitamin K Antagonists. <b>Severity</b> Major <b>Onset</b> Rapid <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased INR/toxic effects of warfarin or other vitamin K antagonists if a sulfonamide is initiated/dose increased, or decreased INR/effects if a sulfonamide is discontinued/dose decreased. Consider reducing warfarin dose by 10-20% prior to starting the sulfonamide antibiotic and then monitoring INR closely to further guide dosing.</p>\n<div>\n <p><b>Sulfonamide Antibiotics Interacting Members</b> SulfADIAZINE, Sulfadoxine, Sulfamethoxazole*, SulfiSOXAZOLE</p>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> A number of reports describe increased effects of warfarin or acenocoumarol within a few days of the initiation of sulfamethoxazole.<sup>1,2,3,4,5,6,7,8</sup> Combined use of sulfamethoxazole-trimethoprim (SMZ-TMP) with warfarin was associated with approximately a 1.7-fold increased odds of hospitalization for gastrointestinal bleeding (compared to warfarin plus cephalexin) in a case-control study of Medicaid data for over 300,000 warfarin users.<sup>9</sup> The time period of greatest risk for hospitalization was 6-10 days after SMZ-TMP initiation. Warfarin-treated patients hospitalized due to an upper gastrointestinal bleed had an almost 4-fold higher odds of having received SMZ-TMP compared to matched controls in a case-control study that included 2151 cases who were warfarin recipients who were hospitalized with an upper gastrointestinal bleed.<sup>10</sup> A retrospective cohort study of 22,272 warfarin recipients who had received an antibiotic similarly concluded that exposure to the combination of warfarin and SMZ-TMP was associated with a 2.1-fold increase in the risk for a patient having serious bleeding listed as a primary or secondary diagnosis within 30 days of antibiotic exposure.<sup>11</sup><br><br>According to a study evaluating pre-emptive warfarin dose reduction, the average INR did not significantly increase following the initiation of SMZ-TMP when warfarin doses were pre-emptively reduced by 10-20% prior to SMZ-TMP initiation.<sup>12</sup> Only 2 of 8 patients whose warfarin doses were pre-emptively reduced had an INR over 4.0 after SMZ-TMP, versus 8 of 9 patients in the control group, where warfarin doses were only adjusted based on observed INR values after SMZ-TMP initiation. Also, none of the 8 SMZ-TMP-treated patients had a subtherapeutic INR during concurrent therapy.<br><br>The mechanisms for these effects are not well-established, but may be multifactorial. The following potential causes have been postulated: 1) sulfonamide displacement of warfarin from protein binding sites; 2) sulfonamide-associated reductions in GI flora responsible for production of vitamin K; and/or 3) sulfonamide-induced reductions in warfarin metabolism (via CYP2C9). Caution is warranted.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Hassall C, Feetam CL, Leach RH, Meynell MJ. Letter: Potentiation of warfarin by co-trimoxazole. <i>Lancet</i>. 1975;2(7945):1155-1156. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=53648\">[PubMed 53648]</a></p>\n<p>2. O'Reilly RA, Motley CH. Racemic warfarin and trimethoprim-sulfamethoxazole interaction in humans. <i>Ann Intern Med</i>. 1979;91(1):34-36. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=464451\">[PubMed 464451]</a></p>\n<p>3. Kaufman JM, Fauver HE Jr. Potentiation of warfarin by trimethoprim-sulfamethoxazole. <i>Urology</i>. 1980;16(6):601-603. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7445308\">[PubMed 7445308]</a></p>\n<p>4. Greenlaw CW. Drug interaction between co-trimoxazole and warfarin. <i>Am J Hosp Pharm</i>. 1979;36(9):1155-1156. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=495610\">[PubMed 495610]</a></p>\n<p>5. Errick JK, Keys PW. Co-trimoxazole and warfarin: case report of aninteraction. <i>Am J Hosp Pharm</i>. 1978;35(11):1399-1401. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=707511\">[PubMed 707511]</a></p>\n<p>6. Greenlaw CW. Drug interaction between co-trimoxazole and warfarin. <i>Am J Hosp Pharm</i>. 1979;36(9):1155-1156. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=495610\">[PubMed 495610]</a></p>\n<p>7. O'Reilly RA. Stereoselective interaction of trimethoprim-sulfamethoxazole with the separated enantiomorphs of racemic warfarin in man. <i>N Engl J Med</i>. 1980;302(1):33-35. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7350395\">[PubMed 7350395]</a></p>\n<p>8. Penning-van Beest FJ, van Meegen E, Rosendaal FR, Stricker BH. Drug interactions as a cause of overanticoagulation on phenprocoumon or acenocoumarol predominantly concern antibacterial drugs. <i>Clin Pharmacol Ther</i>. 2001;69(6):451-457. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11406743\">[PubMed 11406743]</a></p>\n<p>9. Schelleman H, Bilker WB, Brensinger CM, Han X, Kimmel SE, Hennessy S. Warfarin with fluoroquinolones, sulfonamides, or azole antifungals: interactions and the risk of hospitalization for gastrointestinal bleeding. <i>Clin Pharmacol Ther</i>. 2008;84(5):581-588. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18685566\">[PubMed 18685566]</a></p>\n<p>10. Fischer HD, Juurlink DN, Mamdani MM, Kopp A, Laupacis A. Hemorrhage during warfarin therapy associated with cotrimoxazole and other urinary tract anti-infective agents: a population-based study. <i>Arch Intern Med</i>. 2010;170(7):617-621. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20386005\">[PubMed 20386005]</a></p>\n<p>11. Lane MA, Zeringue A, McDonald JR. Serious bleeding events due to warfarin and antibiotic co-prescription in a cohort of veterans. <i>Am J Med</i>. 2014;127(7):657-663. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24657899\">[PubMed 24657899]</a></p>\n<p>12. Ahmed A, Stephens JC, Kaus CA, Fay WP. Impact of preemptive warfarin dose reduction on anticoagulation after initiation of trimethoprim-sulfamethoxazole or levofloxacin. <i>J Thromb Thrombolysis</i>. 2008;26(1):44-48. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17985084\">[PubMed 17985084]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3287":"<p><b>Title</b> Vitamin K Antagonists / Phytonadione</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Phytonadione may diminish the anticoagulant effect of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects (prothrombin time (PT)/ international normalized ratio (INR)) of vitamin K antagonists if phytonadione (vitamin K, either as a vitamin supplement (alone or as part of multiple vitamins or dietary supplements), or as part of vitamin K-rich foods) is initiated/dose increased, or increased effects (PT/INR) if phytonadione is discontinued/dose decreased. Patients should be encouraged to not alter their eating habits concerning vitamin K-rich foods/supplements without consulting their healthcare provider. Examples of vitamin K-rich foods include: Turnip greens, beetroot, broccoli, cabbage, lettuce, liver, asparagus, and spinach.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Several cases reports of vitamin K antagonist “resistance” in patients consuming large daily quantities of vitamin K-rich foods<sup>1,2,3,4,5</sup> or enteral supplements<sup>6,7,8,9,10,11,12,13</sup> have been published. Vitamin K antagonists interfere with the ability of the body to effectively use vitamin K in the production of certain clotting factors (II, VII, IX, X). This interference can be overcome by administering adequate quantities of exogenous vitamin K.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kempin SJ. Warfarin resistance caused by broccoli. <i>N Engl J Med</i>. 1983;308(20):1229-1230. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6843604\">[PubMed 6843604]</a></p>\n<p>2. Karlson B, Leijd B, Hellstrom K. On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment. <i>Acta Med Scand</i>. 1986;220(4):347-350. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3541503\">[PubMed 3541503]</a></p>\n<p>3. Chow WH, Chow TC, Tse TM, Tai YT, Lee WT. Anticoagulation instability with life-threatening complication after dietary modification. <i>Postgrad Med J</i>. 1990;66(780):855-857. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2099431\">[PubMed 2099431]</a></p>\n<p>4. Ovesen L, Lyduch S, Idorn ML. The effect of a diet rich in brussels sprouts on warfarin pharmacokinetics. <i>Eur J Clin Pharmacol</i>. 1988;34(5):521-523. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3203715\">[PubMed 3203715]</a></p>\n<p>5. Kalra PA, Cooklin M, Wood G, O'Shea GM, Holmes AM. Dietary modification as cause of anticoagulation instability. <i>Lancet</i>. 1988;2(8614):803. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2901653\">[PubMed 2901653]</a></p>\n<p>6. O'Reilly RA, Rytand DA. “Resistance” to warfarin due to unrecognized vitamin K supplementation. <i>N Engl J Med</i>. 1980;303(3):160-161. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7383081\">[PubMed 7383081]</a></p>\n<p>7. Westfall LK. An unrecognized cause of warfarin resistance. <i>Drug Intell Clin Pharm</i>. 1981;15(2):131. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7274023\">[PubMed 7274023]</a></p>\n<p>8. Zallman JA, Lee DP, Jeffrey PL. Liquid nutrition as a cause of warfarin resistance. <i>Am J Hosp Pharm</i>. 1981;38(8):1174. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7270565\">[PubMed 7270565]</a></p>\n<p>9. Watson AJ, Pegg M, Green JR. Enteral feeds may antagonise warfarin. <i>Br Med J (Clin Res Ed)</i>. 1984;288(6416):557. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6421377\">[PubMed 6421377]</a></p>\n<p>10. Lader E, Yang L, Clarke A. Warfarin dosage and vitamin K in Osmolite. <i>Ann Intern Med</i>. 1980;93(2):373-374. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7406391\">[PubMed 7406391]</a></p>\n<p>11. Parr MD, Record KE, Griffith GL, Zeok JV, Todd EP. Effect of enteral nutrition on warfarin therapy. <i>Clin Pharm</i>. 1982;1(3):274-276. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6821036\">[PubMed 6821036]</a></p>\n<p>12. Lee M, Schwartz RN, Sharifi R. Warfarin resistance and vitamin K. <i>Ann Intern Med</i>. 1981;94(1):140-141. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7447217\">[PubMed 7447217]</a></p>\n<p>13. Petretich DA. Reversal of osmolite-warfarin interaction by changing warfarin administration time. <i>Clin Pharm</i>. 1990;9(2):93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2106407\">[PubMed 2106407]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3288":"<p><b>Title</b> Vitamin K Antagonists / Zafirlukast</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Zafirlukast may increase the serum concentration of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased International Normalized Ratio (INR) and anticoagulant effects of coumarin derivatives if zafirlukast is initiated/dose increased, or decreased INR/effects if zafirlukast is discontinued/dose decreased.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> In a clinical study described in zafirlukast prescribing information, administration of zafirlukast (160 mg/day) to steady state prior to warfarin (25 mg single dose) increased S-warfarin AUC, S-warfarin half-life, and prothrombin time by 63%, 36%, and 35%, respectively.<sup>1</sup> Zafirlukast pharmacokinetics were unaffected by warfarin coadministration.<br><br>The likely primary mechanism of this interaction is zafirlukast inhibition of CYP2C9 mediated S-warfarin metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Accolate (zafirlukast). Wilmington, DE: AstraZeneca Pharmaceuticals LP, July 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3289":"<p><b>Title</b> Serotonin Reuptake Inhibitor/Antagonists / BusPIRone</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> BusPIRone may enhance the serotonergic effect of Serotonin Reuptake Inhibitor/Antagonists. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The combination of a serotonin reuptake inhibitor/antagonist and buspirone should be undertaken with great caution. When combined treatment is clinically indicated, monitor closely for signs of serotonin toxicity/serotonin syndrome (e.g., confusion, delirium, restlessness, tremors, blushing, diaphoresis, hyperpyrexia).</p>\n<div>\n <p><b>Serotonin Reuptake Inhibitor/Antagonists Interacting Members</b> Nefazodone, TraZODone*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> A single case report describes an elderly man who developed myoclonic movements of the face and arms following one week of concomitant buspirone (5 mg 3 times/day) and trazodone (600 mg/day).<sup>1</sup> <br><br>Buspirone is a partial serotonin receptor (5HT1A) agonist, which could theoretically contribute to central serotonergic excess when used in combination with other serotonergic agents. While this possibility has long been recognized only a few published case reports describe symptoms of serotonin syndrome possibly related to buspirone.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Goldberg RJ and Huk M, “Serotonin Syndrome From Trazodone and Buspirone,” <i>Psychosomatics</i>, 1992, 33:235-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1557493\">[PubMed 1557493]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3290":"<p><b>Title</b> Cardiac Glycosides / Aminoquinolines (Antimalarial)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Aminoquinolines (Antimalarial) may increase the serum concentration of Cardiac Glycosides. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased serum concentrations/toxic effects of cardiac glycosides if an aminoquinoline is initiated/dose increased, or decreased serum concentrations/effects if an aminoquinoline is discontinued/dose decreased.</p>\n<div>\n <p><b>Aminoquinolines (Antimalarial) Interacting Members</b> Chloroquine, Hydroxychloroquine*, Primaquine</p>\n <p><b>Cardiac Glycosides Interacting Members</b> Digitoxin, Digoxin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Two case reports describe patients receiving stable digoxin therapy, whose serum digoxin concentrations were 3 to 4 fold higher during hydroxychloroquine treatment (after 6 to 9 months of treatment, used for rheumatoid arthritis) than 1-2 months after hydroxychloroquine discontinuation.<sup>1</sup> <br><br>The mechanism of these reported effects is unclear, but may be related to hydroxychloroquine inhibition of p-glycoprotein mediated digoxin transport. Chloroquine and primaquine have also been shown to inhibit p-glycoprotein in vitro, and could therefore potentially exert similar effects.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Leden I, “Digoxin-Hydroxychloroquine Interaction?” <i>Acta Med Scand</i>, 1982, 211:411-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7113754\">[PubMed 7113754]</a></p>\n<p>2. Hayeshi R, Masimirembwa C, Mukanganyama S, et al, “The Potential Inhibitory Effect of Antiparasitic Drugs and Natural Products on P-glycoprotein Mediated Efflux,”<i>Eur J Pharm Sci</i>, 2006, 29(1):70-81. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16846720\">[PubMed 16846720]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3291":"<p><b>Title</b> Cardiac Glycosides / 5-Aminosalicylic Acid Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> 5-Aminosalicylic Acid Derivatives may decrease the serum concentration of Cardiac Glycosides. <b>Severity</b> Moderate <b>Onset</b> Rapid <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased serum concentrations/therapeutic effects of cardiac glycosides if a 5-ASA derivative is initiated/dose increased, or increased serum concentrations/effects if a 5-ASA derivative is discontinued/dose decreased.</p>\n<div>\n <p><b>5-Aminosalicylic Acid Derivatives Interacting Members</b> Balsalazide, Mesalamine, Olsalazine, SulfaSALAzine*</p>\n <p><b>Cardiac Glycosides Interacting Members</b> Digitoxin, Digoxin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The AUC of digoxin (0.5 mg single dose of elixir) was decreased 24% in 10 normal subjects when administered following a 6-day regimen of sulfasalazine (either 2 g/day for 6 days OR 2 g for 2 days, then 4 g for 2 days, then 6 g for 2 days).<sup>1</sup> Patients receiving the escalating dosage regimen (n=6) experienced an average decrease in digoxin AUC of 27% (range 6%-55%), whereas the 2 g/day subjects experienced an average decrease of 11% (range 0% to 30%). A case report accompanying this same study showed no difference in the digoxin serum concentrations whether the drugs were administered concurrently or the doses were separated by several hours. Sulfasalazine may inhibit the absorption of digoxin. The mechanism of this effect is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Juhl RP, Summers RW, Guillory JK, et al, “Effect of Sulfasalazine on Digoxin Bioavailability,” <i>Clin Pharmacol Ther</i>, 1976, 20(4):387-94. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10123\">[PubMed 10123]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3292":"<p><b>Title</b> Beta-Blockers / Barbiturates</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Barbiturates may decrease the serum concentration of Beta-Blockers. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of beta-blockers if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. Ophthalmic beta-blockers are not likely of concern.</p>\n<div>\n <p><b>Barbiturates Interacting Members</b> Amobarbital, Butabarbital, Butalbital, Methohexital, PENTobarbital*, PHENobarbital*, Primidone, Secobarbital, Thiopental</p>\n <p><b>Beta-Blockers Interacting Members</b> Acebutolol, Arotinolol, Betaxolol (Ophthalmic), Betaxolol (Systemic), Bisoprolol, Carteolol (Ophthalmic), Carvedilol, Celiprolol, Esmolol, Labetalol, Metoprolol*, Nebivolol, Oxprenolol, Penbutolol, Pindolol, Propranolol*, Sotalol, Timolol (Ophthalmic), Timolol (Systemic)<br><b>Exceptions</b> Atenolol, Levobunolol, Metipranolol, Nadolol</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The AUC of metoprolol was decreased by 32% in 8 normal subjects when administered following a 10-day course of pentobarbital (100 mg/day).<sup>1</sup> A similar effect on both timolol and propranolol has been reported.<sup>2,3</sup> Serum concentrations of alprenolol (not available in U.S.) are approximately halved by barbiturate coadministration.<sup>4,5</sup> Sotolol does not appear to be affected by barbiturate administration.<sup>3</sup> Barbiturates are potent inducers of drug metabolizing enzymes, and many beta-blockers undergo extensive metabolism. Beta-blockers that are primarily excreted as unchanged products in the urine (eg, atenolol, nadolol) would not likely be affected by barbiturates.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Haglund K, Seiderman P, Collste P, et al, “Influence of Pentobarbital on Metoprolol Plasma Levels,” <i>Clin Pharmacol Ther</i>, 1979, 26:326. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=466926\">[PubMed 466926]</a></p>\n<p>2. Mantyla R, Mannisto P, Nykanen S, et al, “Pharmacokinetic Interactions of Timolol With Vasodilating Drugs, Food and Phenobarbitone in Healthy Volunteers,” <i>Eur J Clin Pharmacol</i>, 1983, 24:227-30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6840172\">[PubMed 6840172]</a></p>\n<p>3. Sotaniemi EA, Anttila M, Pelkonen RO, et al, “Plasma Clearance of Propranolol and Sotalol and Hepatic Drug-Metabolizing Activity,” <i>Clin Pharmacol Ther</i>, 1979, 26:153-61. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=455885\">[PubMed 455885]</a></p>\n<p>4. Alvan G, Piafsky K, Lind M, et al, “Effect of Pentobarbital on the Disposition of Alprenolol,” <i>Clin Pharmacol Ther</i>, 1977, 22:316. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=891097\">[PubMed 891097]</a></p>\n<p>5. Collste P, Seideman P, Borg KO, et al, “Influence of Pentobarbital on Effects and Plasma Levels of Alprenolol and 4-Hydroxy-Alprenolol,” <i>Clin Pharmacol Ther</i>, 1979, 25:423-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=428186\">[PubMed 428186]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3294":"<p><b>Title</b> Protease Inhibitors / CarBAMazepine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CarBAMazepine may increase the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of CarBAMazepine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased serum concentrations/toxic effects of carbamazepine if a protease inhibitor is initiated/dose increased, or decreased serum concentrations/effects if a protease inhibitor is discontinued/dose decreased. In addition, monitor for decreased serum concentrations/therapeutic effects of protease inhibitors if carbamazepine is initiated/dose increased, or increased serum concentrations/toxic effects if carbamazepine is discontinued/dose decreased.</p>\n<div>\n <p><b>Protease Inhibitors Interacting Members</b> Atazanavir, Darunavir, Fosamprenavir, Indinavir*, Lopinavir, Nelfinavir*, Ritonavir*, Saquinavir*, Tipranavir</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Case report. Serum carbamazepine concentrations doubled, and symptoms of toxicity developed, in a previously stable patient within 2 days of changing antiretroviral therapy from indinavir/lamivudine/stavudine to nevirapine/ritonavir/saquinavir.<sup>1</sup> The problems resolved following a halving of the carbamazepine dosage and switching ritonavir for nelfinavir. The protease inhibitors are known inhibitors of CYP isoenzymes, including CYP3A4 (a metabolic pathway for carbamazepine). Given the details of the report, it is difficult to name any single protease inhibitor as the causative agent. All of the protease inhibitors could have affected the serum carbamazepine concentrations.<br><br>In addition to these effects, carbamazepine, as a CYP3A4 inducer, carries the potential to increase the metabolism of the protease inhibitors and the risk for therapeutic failure. Consult specific product prescribing information as manufacturers recommend that practitioners monitor for evidence of the occurrence of either of these interactions.The manufacturer of darunavir recommends avoiding concomitant use with carbamazepine.<sup>2,3,4,5,6,7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Mateu-de Antonio J, Grau S, Gimeno-Bayon JL, et al, “Ritonavir-Induced Carbamazepine Toxicity,” <i>Ann Pharmacother</i>, 2001, 35:125-6 (letter). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11197575\">[PubMed 11197575]</a></p>\n<p>2. Agenerase [package insert]. Research Triangle Park, NC: Glaxo Wellcome, 1999.</p>\n<p>3. Viracept [package insert]. La Jolla, CA: Agouron Pharmaceuticals, Inc, 1997.</p>\n<p>4. Fortovase [package insert]. Nutley, NJ: Roche Laboratories, Inc, 1997.</p>\n<p>5. Crixivan [package insert]. West Point, PA: Merck &amp; Co, 2000.</p>\n<p>6. Norvir [package insert]. North Chicago, IL: Abbot Laboratories, 2000.</p>\n<p>7. Prezista [package insert]. Raritan, NJ: Tibotec Therapeutics, 2006.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3295":"<p><b>Title</b> Quinolones / Zinc Salts</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (oral): Only oral preparations of zinc salts and quinolone antibiotics are expected to participate in this interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Zinc Salts may decrease the serum concentration of Quinolones. <b>Severity</b> Moderate <b>Onset</b> Immediate (Sequence Important) <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Administer oral quinolones at least several hours before (4 h for moxi- and sparfloxacin, 2 h for others) or after (8 h for moxifloxacin, 6 h for ciprofloxacin and delafloxacin, 4 h for lomefloxacin, 3 h for gemifloxacin, 2 h for levo-, nor-, pe- or ofloxacin or nalidixic acid) oral zinc salts. Monitor for diminished effects of the quinolone if this duration of dose separation cannot be achieved.</p>\n<div>\n <p><b>Quinolones Interacting Members</b> Ciprofloxacin (Systemic)*, Delafloxacin, Gemifloxacin, LevoFLOXacin (Systemic), Lomefloxacin, Moxifloxacin (Systemic), Nalidixic Acid, Norfloxacin*, Ofloxacin (Systemic), Pefloxacin, Pipemidic Acid, Sparfloxacin<br><b>Exception</b> LevoFLOXacin (Oral Inhalation)</p>\n <p><b>Zinc Salts Interacting Members</b> Polaprezinc, Zinc Acetate, Zinc Gluconate, Zinc Sulfate*<br><b>Exception</b> Zinc Chloride</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The absorption of ciprofloxacin (500 mg single oral dose) was decreased by 24% when administered following (and concurrent with the last dose of) a 7-day course of a daily multivitamin containing 23.9 mg zinc.<sup>1</sup> Another report describes a greater than 50% reduction in norfloxacin absorption due to concomitant zinc sulfate administration.<sup>2</sup> The suspected primary mechanism of these interaction formation of an insoluble complex between the antibiotic and the zinc ion that is not readily absorbed from the GI tract. Specific dose separation recommendations aimed at minimizing such interactions are offered by manufacturers of oral quinolone products.<sup>3,4,5,6,7,8,9,10,11,12</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Polk RE, Healey DP, Sahai J, et al, “Effect of Ferrous Sulphate and Multivitamins With Zinc on the Absorption of Ciprofloxacin in Normal Volunteers,” <i>Antimicrob Agents Chemother</i>, 1989, 33:1841-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2610494\">[PubMed 2610494]</a></p>\n<p>2. Campbell NR, Kara M, Hasinoff BB, et al, “Norfloxacin Interaction With Antacids and Minerals,” <i>Br J Clin Pharmacol</i>, 1992, 33:115-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1540482\">[PubMed 1540482]</a></p>\n<p>3. Prescribing information. Factive (gemifloxacin). Cary, NC: Cornerstone Therapeutics Inc., October 2011.</p>\n<p>4. Prescribing information. Maxaquin (lomefloxacin). New York, NY: Pfizer Inc, March 2005.</p>\n<p>5. Prescribing information. Zagam (sparfloxacin). Research Triangle Park, NC: Bertek Pharmaceuticals Inc., 4/2003.</p>\n<p>6. Prescribing information. Noroxin (norfloxacin). Whitehouse Station, NJ: Merck &amp; Co., Inc., 3/2013.</p>\n<p>7. Prescribing information. Cipro (ciprofloxacin). Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc., 1/2013.</p>\n<p>8. Prescribing information. Levaquin (levofloxacin). Titusville, NJ: Janssen Pharmaceuticals, Inc., April 2012.</p>\n<p>9. Prescribing information. NegGram (nalidixic acid). Bridgewater, NJ: Sanofi-Aventis U.S. LLC, 11/2012.</p>\n<p>10. Product monograph. Ofloxacin. Toronto, ON: AA Pharma Inc., May 2010.</p>\n<p>11. Baxdela (delafloxacin) [prescribing information]. Lincolnshire, IL: Melinta Therapeutics Inc; June 2017.</p>\n<p>12. Pefloxacin tablet [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199101448 Accessed October 26, 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3296":"<p><b>Title</b> DiazePAM / Lithium</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Lithium may enhance the adverse/toxic effect of DiazePAM. Specifically, the development of hypothermia. <b>Severity</b> Major <b>Onset</b> Delayed <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> No action necessary.</p> \n<p><b>Discussion</b> A patient developed hypothermia (on more than 1 occasion) while taking both lithium and diazepam, but not while receiving either drug alone.<sup>1</sup> <br><br>The mechanism of any potential drug interaction between these agents is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Naylor GJ and McHarg A, “Profound Hypothermia on Combined Lithium Carbonate and Diazepam Treatment,” <i>Br Med J</i>, 1977, 3:22. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=871741\">[PubMed 871741]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3299":"<p><b>Title</b> Theophylline Derivatives / Interferons</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Interferons may decrease the metabolism of Theophylline Derivatives. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased serum concentrations/toxic effects of theophylline if an interferon is initiated/dose increased, or decreased serum concentrations/effects if an interferon is discontinued/dose decreased.</p>\n<div>\n <p><b>Interferons Interacting Members</b> Interferon Alfa-2a, Interferon Alfa-2b, Interferon Alfa-n3, Interferon Alfacon-1, Interferon Beta-1a, Interferon Beta-1b, Interferon Gamma-1b, Peginterferon Alfa-2a, Peginterferon Alfa-2b, Peginterferon Beta-1a</p>\n <p><b>Theophylline Derivatives Interacting Members</b> Acebrophylline, Aminophylline, Theophylline*<br><b>Exception</b> Dyphylline</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The clearance of theophylline (5 mg/kg IV) was decreased by 33% to 81% in patients and normal subjects (4 each) when administered 20 hours after a single dose of interferon alpha<sub>2</sub>A (9 or 18 million units).<sup>1</sup> Subjects with pre-existing increased clearance of theophylline (eg, smokers) were affected more than other subjects. The clearance of theophylline (aminophylline 4 mg/kg single IV dose) was decreased only 10% in 11 normal subjects when administered following a 3-day course of interferon alpha<sub>2</sub>A (3 million units/day).<sup>2</sup> It would appear that interferon alpha may inhibit the metabolism of theophylline. The mechanism is unclear. Higher interferon doses (eg, 9 million units/day) appear to affect theophylline clearance more than lower doses (eg, 3 million units/day). Laboratory studies indicate that interferon alpha and gamma may downregulate CYP1A2 activity.<sup>3,4,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Williams SJ, Baird-Lambert JA, and Farrell GC, “Inhibition of Theophylline Metabolism by Interferon,” <i>Lancet</i>, 1987, ii:939-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2444839\">[PubMed 2444839]</a></p>\n<p>2. Jonkman JH, Nicholson KG, Farrow PR, et al, “Effects of Alpha-Interferon on Theophylline Pharmacokinetics and Metabolism,” <i>Br J Clin Pharmacol</i>, 1989, 27:795-802. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2757895\">[PubMed 2757895]</a></p>\n<p>3. Abdel-Razzak Z, Loyer P, Fautrel A, “Cytokines Down-regulate Expression of Major Cytochrome P-450 Enzymes in Adult Human Hepatocytes in Primary Culture,” <i>Mol Pharmacol</i>, 1993, 44(4):707-15. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8232220\">[PubMed 8232220]</a></p>\n<p>4. Abdel-Razzak Z, Corcos L, Fautrel A, et al, “Transforming Growth Factor-Beta 1 Down-regulates Basal and Polycyclic Aromatic Hydrocarbon-induced Cytochromes P-450 1A1 and 1A2 in Adult Human Hepatocytes in Primary Culture,” <i>Mol Pharmacol</i>, 1994, 46(6):1100-10. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7808430\">[PubMed 7808430]</a></p>\n<p>5. Bleau AM, Levitchi MC, Maurice H, et al, “Cytochrome P450 Inactivation by Serum from Humans With a Viral Infection and Serum from Rabbits With a Terpentine-induced Inflammation: the Role of Cytokines,” <i>Br J Pharmacol</i>, 2000, 130(8):1777-84. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10952665\">[PubMed 10952665]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}